

Received at: 12:10PM, 1/7/2004

JAN-07-2004 09:19 FROM:

JAN 12 2004

TO: 817034132220

P.002/004



DOCKET NO: 219148US0CONT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF

THOMAS RITTER, ET AL.

SERIAL NO: 10/068,916

FILED: FEBRUARY 11, 2002

FOR: GENETICALLY MODIFIED T-CELLS, METHOD FOR PRODUCING THEM AND USE THEREOF

: EXAMINER: MARVICH

: GROUP ART UNIT: 1636

RECEIVED

JAN 20 2004

DECLARATION UNDER 37 C.F.R. 1.132

TECH CENTER 1600/2900

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:

Now comes Jerzy W. Kupiec-Weglinski, M.D., Ph.D. who states that:

1. I am Professor of Surgery and Pathology at UCLA, and hold the endowed Goldwyn Chair in Transplantation Immunobiology.
2. I have been working in the transplantation arena for over 25 years now, including 18 years at Harvard. I authored over 350 referred papers in the scientific literature that focus on organ transplantation. My curriculum vitae is attached as Exhibit 1.
3. I have read and understand the contents of the above-identified patent application.
4. It is my understanding that a point of contention in this application is whether it would require undue experimentation to make and use the *in vitro* modified T cells described and claimed in this patent application.
5. First of all, I would like to state that the idea of using ex-vivo generated alloantigen-specific T cells from transplant recipient as carriers for immunomodulatory molecules, both in the transplant itself and in the secondary

Application No. 10/068,916  
Reply to Office Action of

lymphoid organs (lymph nodes or spleen), is a novel one. Indeed, it is a highly desirable approach, as the likelihood that such T cells could replace other currently applied immunosuppressive drugs without severe side effects is potentially high. Moreover, it may well fulfill the elusive goal of transplantation of creating a true tolerance only after a short-term treatment.

6. Second, there is no doubt that some safety concerns related to the retrovirus-mediated gene transfer should be taken into the account. However, it is my understanding that in Dr. Ritter's proposal the generation of alloantigen-specific T cells by retrovirus-mediated gene transfer is not the sole technique that will be employed. Although retrovirus-mediated gene transfer is the most efficient technique to transduce T cells nowadays, it is plausible that other more efficient techniques will be developed in the near future for this particular application. However, at present retrovirus-mediated gene transfer is still the prominent and acceptable technique in human trials despite safety concerns when T cells or hematopoietic stem cells are the target of therapy.
7. Third, I find Dr. Ritter's in vitro results with IL-10 modified T cells to be most fascinating and promising. The approach of generating regulatory cells *ex vivo* with regulatory in vivo properties has been recently reported. Indeed, Hori et al. have shown very promising data on the generation of regulatory T cells by retrovirus-mediated gene transfer of foxP3 in T cells in autoimmune models (*Science*, 2003; 299:1057-1060). Thus, based on my knowledge of the field, I am convinced that in vitro IL-10 modified T cells will exert potent regulatory functions *in vivo*.
8. At the end let me stress again my high enthusiasm for that innovative and clinically applicable patent application.


JAN-07-2004 09:20 FROM:

TO: 817034132220

P.004/004

Application No. 10/068,916  
Reply to Office Action of

9. I declare under penalty of perjury that the foregoing is believed to be true and  
accurate.

  
Jerzy W. Kupiec-Weglinski, M.D., Ph.D.

01/07/04

Date

## CURRICULUM VITAE

### JERZY W. KUPIEC-WEGLINSKI, M.D, Ph.D.

#### *Personal Information:*

**Business Address:** The Dumont-UCLA Transplant Center  
Division of Liver and Pancreas Transplantation  
10833 Le Conte Ave., 77-120 CHS  
Los Angeles, CA 90095  
**Business Phone:** (310) 825-4196  
**Business Fax:** (310) 267-2358  
**Business E-Mail:** JKUPIEC@MEDNET.UCLA.EDU

**Date of Birth:** July 11, 1951  
**Place of Birth:** Warsaw, Poland  
**Citizenship:** USA  
**Marital Status:** Married ; Wife:Kasia ; 1 child: Sophie-Ann  
**Home address:** 1735 San Ysidro Dr., Beverly Hills, CA 90210  
**Home Phone:** (310) 385-8467

#### *Education:*

1969 College of Warsaw, Poland  
1974 M.D. - Warsaw Medical School, Poland  
1979 Ph.D. - Department of Surgical Research and Transplantology, Medical Research Center, Polish Academy of Sciences, Warsaw, Poland

#### *Postdoctoral Training:*

##### *Internships and Residencies:*

1975 - 1978 Rotating Internship, Clinics of Warsaw Medical School  
1976 - 1978 Physician to Out-Patients, Warsaw Medical School  
1976 - 1978 Resident in Internal Medicine, Clinic of Gastroenterology and Metabolic Diseases, Warsaw Medical School  
1978 Senior Resident

##### *Research Fellowships:*

1975 - 1979 Department of Surgical Research and Transplantology, Medical Research Center, Polish Academy of Sciences, Warsaw, Poland. February 1979. Ph.D. thesis: "The migration of <sup>51</sup>Cr- and <sup>125</sup>IUDR-labelled lymphocytes in normal rat".  
1975 Exchange Fellow in Surgery, St. Paul's Hospital, Barcelona, Spain  
1976 Exchange Fellow in Surgery, Central Institute of Diabetes, Karlsburg, Germany  
1986 (9 months) Horatio Symmonds Fellow, Nuffield Department of Surgery, University of Oxford, John Radcliffe Hospital, and MRC Cellular Immunology Unit, Sir William Dunn School of Pathology, Oxford, UK

#### *Licensure and Certification:*

1975 M.D., Warsaw, Poland  
1978 Medical Licence for Private Practice in Internal Medicine and Surgery, Warsaw  
1979 Ph.D., Warsaw

#### *Academic Appointments:*

1976	Junior Assistant in Surgical Research, Polish Academy of Sciences
1978	Senior Assistant
1979	Assistant Professor
1979 - 1981	Research Fellow in Surgery, Harvard Medical School, Boston, MA
1982 - 1984	Instructor in Surgery, Harvard Medical School
1985 - 1987	Assistant Professor of Surgery, Harvard Medical School
1987 - 1997	Associate Professor of Surgery, Harvard Medical School
1997 -	Professor of Surgery, University of California School of Medicine at Los Angeles
2001 -	Professor of Pathology and Laboratory Medicine, University of California School of Medicine at Los Angeles
2002 -	Joan S. and Ralph N. Goldwyn Chair in Immunobiology and Transplantation Research, UCLA

#### *Awards/Honors:*

1996	Habilitation; Polish Academy of Sciences, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland
2002	Honorary Doctorate (Honoris Causa); Warsaw Medical Academy, Poland

#### *Major Committee Assignments in Professional Societies:*

1986 -	Member, Editorial Board, TRANSPLANTATION
1986 -	Reviewer, SCIENCE, JOURNAL OF CLINICAL INVESTIGATION, JOURNAL OF IMMUNOLOGY, ANNALS OF SURGERY, HYBRIDOMA, JASN, etc.
1988	Scientific Co-Chairperson, XII International Congress of The Transplantation Society, Sydney, Australia
1990	Scientific Co-Chairperson, IX Annual Meeting of The American Society of Transplant Physicians, Chicago, IL
1990	Abstract Review Panelist, XIII International Congress of The Transplantation Society, San Francisco, CA
1990	Scientific Co-Chairperson, XIII International Congress of The Transplantation Society, San Francisco, CA
1991 -	Ad-hoc reviewer: National Institutes of Health, Veterans Health Administration, The Kidney Foundation of Canada
1992	Abstract Review Panelist, XIV International Congress of The Transplantation Society, Paris, France
1992	Scientific Co-Chairperson, XIV International Congress of The Transplantation Society, Paris, France
1993	Scientific Co-Chairperson, XII Annual Meeting of The American Society of Transplant Physicians, Houston, TX
1993	International Scientific Advisory Committee, III Basic Sciences Symposium of The Transplantation Society, Big Sky, MT
1993 - 1995	Scientific Studies Committee of the American Society of Transplant Physicians
1993 -	Member, Editorial Board, TRANSPLANT IMMUNOLOGY
1994	Scientific Co-Chairperson, XIII Annual Meeting of The American Society of Transplant Physicians, Chicago, IL
1994	Abstract Review Panelist, XV World Transplantation Congress, Kyoto, Japan
1994	Scientific Co-Chairperson, XV World Transplantation Congress, Kyoto, Japan
1995	International Scientific Advisory Committee, IV Basic Sciences Symposium of The Transplantation Society, Noordwijkerhout, Holland
1995	Scientific Co-Chairperson, XIV Annual Meeting of The American Society of Transplant Physicians, Chicago, IL
1995	Scientific Co-Chairperson, IV Basic Sciences Symposium of The Transplantation Society, Noordwijkerhout, Holland
1996	Abstract Review Panelist, XVI International Congress of The Transplantation Society, Barcelona, Spain
1996	Abstract Review Panelist, XV Annual Meeting of The American Society of Transplant Physicians, Dallas, TX

1996 Scientific Co-Chairperson, XV Annual Meeting of The American Society of Transplant Physicians, Dallas, TX

1996 - Member, Editorial Board, ANNALS OF TRANSPLANTATION

1996 Scientific Co-Chairperson, XVI International Congress of The Transplantation Society, Barcelona, Spain

1996 - Awards Committee of the American Society of Transplant Physicians

1996 Scientific Co-Chairperson, VI International Alexis Carrel Conference, Banff, Canada

1997 Abstract Review Panelist, XVI Annual Meeting of The American Society of Transplant Physicians, Chicago, IL

1997 Scientific Co-Chairperson, XVI Annual Meeting of The American Society of Transplant Physicians, Chicago, IL

1997 - Member, Editorial Board, FRONTIERS IN BIOSCIENCE

1998 Scientific Co-Chairperson, XVII Annual Meeting of The American Society of Transplant Physicians, Chicago, IL

1998 Abstract Review Panelist, XVII International Congress of The Transplantation Society, Montreal, Canada

1998 - Member, Editorial Board, GRAFT

1998 Scientific Co-Chairperson, XVII International Congress of The Transplantation Society, Montreal, Canada

1998 Ad-hoc Member, Surgery, Anesthesiology and Trauma Study Section, NIH

1999 Co-Chair, Basic Science Abstract Review Panelist, XVII Annual Meeting of The American Society of Transplant Physicians, Chicago, IL

2000 Co-Chair, Abstract Review Committee, Transplant 2000, Chicago, IL

2000 Program Planning Committee Transplant 2000, Chicago, IL

2000 Scientific Co-Chairperson, XVIII International Congress of The Transplantation Society, Rome, Italy

2000 Program Planning Committee Transplant 2001, Chicago, IL

2000 - Member, Awards Committee, American Society of Transplantation

2000 - Member, Basic Science Committee, American Society of Transplantation

2000 - Vice Chair, Awards Committee, American Society of Transplant Surgeons

2000-2001 Editorial Board, 2<sup>nd</sup> International Congress on Immunosuppression, San Diego, CA

2001 Program Planning Committee, American Transplantation Congress 2002, Washington, DC

2001 Program Planning Committee, 2<sup>nd</sup> Winter Symposium of American Society of Transplant Surgeons, Miami, FL

2002 - Board of Directors, American Society of Transplantation

2002 Abstract Review Panelist, XIX International Congress of Transplantation Society, Miami, FL

2002 Scientific Co-Chairperson, XIX International Congress of Transplantation Society, Miami, FL

2003 Co-Chair, Basic Science Section; NIH Consensus Conference on Humoral Rejection, Bethesda, MD

#### *Memberships in Professional Societies:*

1982 - American Federation for Clinical Research

1982 - International Society for Heart Transplantation

1984 - The Transplantation Society

1985 - American Association of Immunologists

1991 - American Society of Transplant Physicians

1998 American Society of Transplantation

1999- American Society of Transplant Surgeons

#### *Major Research Interests:*

Transplantation - host responses to vascularized organ allografts

Immunobiology - host immunomodulation by CD4/CD25 targeted therapies, CsA, Rapamycin

- cytokine networks in graft recipients

Immunology - cell surface receptors

- migration and homing of lymphoid cells

- role of the extracellular matrix proteins in lymphocyte recirculation

#### *Research Funding Information:*

##### *Current:*

- 2003 - 2008 USPHS RO1 DK062357: "Heme Oxygenase-1 in Hepatic Ischemia/Reperfusion Injury" (PI)  
2001 - 2007 USPHS RO1 AI 23847: "Costimulatory Pathways in Sensitized Graft Recipients" (PI)  
1998 - 2003 USPHS RO1 AI 42223: "Infectious Tolerance in Transplant Recipients" (PI)

##### *Past:*

- 1981 - 1985 Biomedical Research Support Grants, Brigham and Women's Hospital  
1985 - 1986 William F. Milton Fund: "IL-2 Receptor Targeted Therapy in Organ Transplantation"  
1986 Horatio Symmonds Scholarship, Nuffield Department of Surgery, Oxford University  
1987 - 1989 American Heart Association Grant-In-Aid Award: "Anti IL-2 Receptor Therapy in Transplantation" (PI)  
1988 - 1991 USPHS RO1 Grant: "Anti IL-2 Receptor MoAb and Cyclosporine in Grafted Hosts" (PI)  
1990 - 1991 NATO Grant: "Biological Bases of Drug Interactions in Organ Transplantation" (PI)  
1990 - 1992 SmithKline Beecham Pharmaceuticals Grants: "Evaluation of Therapeutic Efficacy of SK&F 105,685 and Rapamycin in Organ Transplantation"  
1991 - 1996 USPHS RO1 Grant: "CD4/CD25 Targeted Therapy in Sensitized Graft Recipients" (PI)  
1992 - 1997 USPHS RO1 Grant: "Mechanisms of Chronic Rejection of Kidney Allografts" (Co-Invest)  
1996 - 1997 William F. Milton Fund: "Novel Therapy for Chronic Rejection by Using Fibronectin Peptides" (PI)  
1996 - 1999 NATO Grant: "Nondepleting CD4-Targeted Immunosuppressive Therapy in Sensitized Allograft Recipients" (PI)  
1998 - 2001 Athena Neuroscience Inc. Educational Grant: "VLA-4-Targeted Therapy in Organ Transplantation" (PI)  
1999 - 2002 SangStat Corp. Grant: "The Role of Heme Oxygenase in Ischemia/Reperfusion Injury" (PI)  
2000 - 2002 University of California BISTAR Grant: "Heme Oxygenase in Liver Ischemia/Reperfusion Injury" (PI)

#### *Teaching Experience:*

- 1981 - Grand Rounds presentations  
1984 - Supervising post-doctoral fellows and surgical residents

#### *Invited Lectures (selected):*

- 1982 VII International Congress in Microsurgery, Lyon, France  
1985 Bone Marrow Transplant Unit, The Johns Hopkins School of Medicine, Baltimore, MD  
1986 Institute of Immunology, Free University, West Berlin, Germany  
1986 Institute of Immunology & Oncology, BAYER AG, Wuppertal, Germany  
1986 Department of Experimental Surgery, State University, Groningen, Holland  
1986 Nuffield Department of Surgery, John Radcliffe Hospital, Oxford, UK  
1986 Department of Immunology, University of Manchester, UK  
1987 Sandoz Research Institute, East Hanover, NJ  
1987 Workshop on Transplant Tolerance: Rationale and Application, Bar Harbor, ME  
1987 Joint Meeting of The French Transplant and Immunological Society, Paris, France  
1987 Institute of Immunology, University of Nantes, France  
1988 International Symposium on Transplantation Immunology, West Berlin, Germany  
1988 Department of Surgery, Columbia University, New York, NY  
1988 Reconstructive Microsurgery & Transplant Lab, University of California, Irvine, CA  
1988 International Symposium on Inflammatory Heart Disease, Snowmass, CO  
1989 Department of Surgery, The German Heart Center, West Berlin, Germany  
1989 Department of Surgery & Immunology, Mayo Clinic, Rochester, MN  
1989 IV Congress of The European Society for Organ Transplantation, Barcelona, Spain  
1990 X Meeting of The Mexican Transplantation Society, Mexico City, Mexico  
1990 Department of Surgery, Klinik rechts der Isar, Munich, Germany  
1990 Symposium on The Experimental Models in Transplantation Surgery, Cortona, Italy  
1990 International Conference on Monoclonal Antibodies for Clinical Use, London, UK  
1990 II Congress of The Brazilian Association for Organ Transplantation, Canela, Brazil  
1991 Federation of American Societies for Experimental Biology, Atlanta, GA  
1991 Workshop on Composite Tissue Transplantation, Seattle, WA  
1991 Department of Pathology & Surgery, University of Florida, Gainesville, FL  
1992 Molecular Mechanisms of T Cell Regulation in Transplantation, Paris, France  
1992 Workshop on Immunology of Corneal Transplantation, Reimsburg-Ulm, Germany  
1993 XII Annual Meeting of The American Society of Transplant Physicians, Houston, TX

1993 Department of Pharmaceutics, State University of New York, Buffalo, NY  
 1993 III Basic Sciences Symposium of The Transplantation Society, Big Sky, MT  
 1993 Symposium on Cell Adhesion Molecules in Immunopathology, Warsaw, Poland  
 1993 Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland  
 1994 Department of Surgery, Asahikawa Medical College, Asahikawa, Japan  
 1994 Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan  
 1994 National Children's Medical Research Center, Tokyo, Japan  
 1994 Department of Surgery, Queen Mary Hospital, Hong Kong  
 1994 Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA  
 1995 International Symposium "Progress in Transplantation", Warsaw, Poland  
 1995 J. Humphrey Course on Modulation of the Immune Response, Holzgau, Germany  
 1995 Symposium on the Extracellular Matrix in Transplantation, Porto, Portugal  
 1996 International Symposium "Progress in Transplantation", Warsaw, Poland  
 1996 Tibor Diamantstein-Gedenksymposium, Berlin, Germany  
 1996 XV Annual Meeting of The American Society of Transplant Physicians, Dallas, TX  
 1996 The University of Illinois, College of Medicine, Chicago, IL  
 1996 The Dumont-UCLA Transplant Center, Los Angeles, CA  
 1996 International Conference "Organ and Tissue Transplantation", Prague, Czech Republic  
 1996 VI International Alexis Carrel Conference, Banff, Alberta, Canada  
 1997 First ASTP Winter Symposium, Phoenix, AZ  
 1997 XVI Annual Meeting of The American Society of Transplant Physicians, Chicago, IL  
 1997 29th International Conference on Transplantation and Clinical Immunology, Lyon, France  
 1997 The International Congress on Immunosuppression, Orlando, FL  
 1998 Sandoz Center for Immunobiology, Harvard Medical School, Boston, MA  
 1998 Institute of Medical Immunology, Humboldt University, Berlin, Germany  
 1999 Harvard Medical School, Boston, MA  
 2000 4<sup>th</sup> Annual Winter Symposium, American Society of Transplantation, Puerto Rico  
 2000 Transplant 2000, Chicago, IL  
 2000 26<sup>th</sup> Annual Meeting of American Society of Histoincompatibility and Immunogenetics, Orlando, FL  
 2000 The Thomas Starzl Transplantation Institute, Pittsburgh, Pennsylvania  
 2000 The Max Planck Institute, Berlin, Germany  
 2001 6<sup>th</sup> International Conference on Tolerance Induction, Tucson, AZ  
 2001 5<sup>th</sup> Annual Winter Symposium, American Society of Transplantation, Island of Hawaii  
 2001 The Cleveland Clinic Foundation, Cleveland, OH  
 2001 Transplant 2001, Chicago, IL  
 2001 6<sup>th</sup> Annual Meeting of The Japanese Society for Liver Transplantation, Yokohama, Japan  
 2001 Department of Surgery, Showa University, Tokyo, Japan  
 2001 Department of Surgery, University of Maryland Medical School, Baltimore, MD  
 2001 The Second International Congress on Immunosuppression, San Diego, CA  
 2002 The Second Winter Symposium of American Society of Transplant Surgeons, Miami Beach, FL  
 2002 The American Transplantation Congress, Washington, DC  
 2002 Progress in Organ Transplantation, Taichung, Taiwan  
 2002 International Liver Transplantation Society 8th Congress, Chicago, IL  
 2002 XIX International Congress of The Transplantation Society, Miami, FL  
 2002 International Symposium on Moral, Legal and Ethical Aspects of Transplantation, Warsaw, Poland  
 2003 NIH Consensus Conference on Humoral Rejection, Bethesda, MD  
 2003 The Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, MD  
 2003 The American Transplantation Congress, Washington, DC  
 2003 International Conference on HO-1 and CO, Uppsala, Sweden



## BIBLIOGRAPHY

Jerzy W. Kupiec-Weglinski, M.D., Ph.D.

### PEER REVIEWED RESEARCH ARTICLES:

1. Kupiec-Weglinski JW, Olszewski WL: Lymphocyte recirculation through the non-lymphoid tissues of normal rats. *Arch. Immunol. et Ther. Exp.* 1978; 26:381-8.
2. Olszewski WL, Kupiec-Weglinski JW: Whole body localization of intravenously injected lymphoblasts in normal rats. *Lymphology* 1978; 11:222-30.
3. Kupiec-Weglinski JW, Tilney NL: Migration patterns of lymphocytes from recipients of organ allografts. I. The unmodified host. *Transplantation* 1981; 32:121-7.
4. Baldwin WM III, McKean WP, Clason AC, Bordes-Aznar J, Kupiec-Weglinski JW, Tilney NL: Selective localization of cortical thymocytes to cardiac allografts in enhanced rats. *Transplantation* 1982; 33:200-2.
5. Kupiec-Weglinski JW, Bordes-Aznar J, Clason AE, Duarte AJS, Araneda D, Carpenter CB, Strom TB, Tilney NL: Migration patterns of lymphocytes in untreated and immunologically manipulated recipients of organ allografts. *Transplantation* 1982; 33:593-8.
6. Clason AE, Duarte AJS, Kupiec-Weglinski JW, Williams JN, Wang BS, Strom TB, Tilney NL: Restoration of allograft responsiveness in B rats by interleukin 2 and/or adherent cells. *J. Immunol.* 1982; 129:252-9.
7. Bordes-Aznar J, Kupiec-Weglinski JW, Duarte AJS, Milford EL, Strom TB, Tilney NL: Function and migration of suppressor lymphocytes from Cyclosporine- treated heart graft recipients. *Transplantation* 1983; 35: 185-90.
8. Rowinski WA, Kupiec-Weglinski JW, Tilney NL: Migration patterns of lymphocytes from recipients of organ allografts. II. The enhanced host. *Transplantation* 1983; 36:467-9.
9. Lear PA, Heidecke CD, Kupiec-Weglinski JW, Araneda D, Strom TB, Tilney NL: Restoration of allograft responsiveness in B rats. II. Requirements for lymphoid populations and lymphokine. *Transplantation* 1983; 36:412-7.
10. Kupiec-Weglinski JW, Lear PA, Heidecke CD, Araneda D, Tilney NL: Restoration of allograft responsiveness in B rats. IV. The divergent migratory behavior of lymphocyte populations mediating cardiac allograft rejection. *Cell. Immunol.* 1984; 85:459-76.
11. Kupiec-Weglinski JW, Lear PA, Heidecke CD, Tilney NL: Modification of function and migration patterns of thymocyte populations by Cyclosporine after organ transplantation in rats. *Transplantation* 1984; 37:631-3.
12. Heidecke CD, Kupiec-Weglinski JW, Lear PA, Abbud-Filho M, Araujo JL, Araneda D, Strom TB, Tilney NL: Interactions between T lymphocyte subsets supported by interleukin 2-rich lymphokines produce rejection of vascularized cardiac allografts in T cell deprived rats. *J. Immunol.* 1984; 133:582-8.
13. Abbud-Filho M, Kupiec-Weglinski JW, Araujo JL, Heidecke CD, Tilney NL, Strom TB: Cyclosporine therapy of rat heart allograft recipients and release of interleukins (IL 1, IL 2, IL 3): A role for IL 3 in graft tolerance? *J. Immunol.* 1984; 133:2582-6.
14. Kupiec-Weglinski JW, Abbud-Filho M, Strom TB, Tilney NL: Sparing of suppressor cells: A critical action of Cyclosporine. *Transplantation* 1984; 38:97-101.
15. Araujo JL, Kupiec-Weglinski JW, Araneda D, Towpik E, Heidecke CD, Williams JM, Tilney NL: Phenotype, activation status, and suppressor activity of host lymphocytes during acute rejection and after Cyclosporine-induced unresponsiveness of rat cardiac allografts. *Transplantation* 1985; 40:278-84.
16. Kupiec-Weglinski JW, Heidecke CD, Araujo JL, Abbud-Filho M, Towpik E, Araneda D, Strom TB, Tilney NL: Behavior of helper T lymphocytes in Cyclosporine-mediated long-term graft acceptance in the rat. *Cell. Immunol.* 1985; 93:168-77.

17. Heidecke CD, Araujo JK, Kupiec-Weglinski JW, Abbud-Filho M, Araneda D, Stadler J, Siewert J, Strom TB, Tilney NL: Lack of evidence for an active role for natural killer cells in acute rejection of organ allografts. **Transplantation** 1985; 40:441-4.
18. Kupiec-Weglinski JW, Araujo JL, Towpik E, Araneda D, Tilney NL: Host - graft relationship: The systemic nature of allograft rejection. **Surgery** 1985; 98:259-65.
19. Uhteg LC, Salomon DR, Rocher LL, Kupiec-Weglinski JW, Araujo JL, Rubin MF, Tilney NL, Carpenter CB: Cyclosporine-induced transplantation unresponsiveness in rat cardiac allograft recipients: In vitro determination of helper and suppressor activity. **J. Immunol.** 1985; 135:1800-5.
20. Towpik E, Kupiec-Weglinski JW, Schneider TM, Tyler D, Padberg W, Araneda D, Tilney NL: Cyclosporine and experimental skin allografts. II. Indefinite survival and development of specific immunologic unresponsiveness. **Transplantation** 1985; 40:714-8.
21. Huber DJ, Kirkman RL, Kupiec-Weglinski JW, Araujo JL, Tilney NL, Adams DF: The detection of cardiac allograft rejection by alterations in proton NMR relaxation times. **Invest. Radiology** 1985; 20:796-802.
22. Kupiec-Weglinski JW, Towpik E, Schneider TM, Araneda D, Ma L, Tilney NL: T suppressor lymphocytes reverse ongoing acute allograft rejection. **Hum. Immunol.** 1985; 14:270-8.
23. Kupiec-Weglinski JW, de Sousa M, Tilney NL: The importance of lymphocyte migration patterns in experimental organ transplantation. **Transplantation** 1985; 40:1-6.
24. Towpik E, Kupiec-Weglinski JW, Tilney NL: The potential use of Cyclosporine in reconstructive surgery. **Plast. Rec nstr. Surg.** 1985; 76:312-22.
25. De Sousa M, Carroll AM, Kupiec-Weglinski JW, Tilney NL: Regulation of lymphoid cell traffic. **Immunol. T day** 1985; 6:319-20.
26. Towpik E, Kupiec-Weglinski JW, Tyler DS, Araujo JL, Schneider TM, Murphy GM, Tilney NL: Cyclosporine and experimental skin allografts: Long-term survival in rats treated with low maintenance doses. **Plast. Reconstr. Surg.** 1986; 77:268-76.
27. Kupiec-Weglinski JW, Diamantstein T, Tilney NL, Strom TB: Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats. **Proc. Natl. Acad. Sci. USA** 1986; 83:2624-7.
28. Guillen FJ, Hancock WW, Towpik E, Kupiec-Weglinski JW, Rickles FR, Tilney NL, Murphy GF: Inhibition of rat skin allograft rejection by Cyclosporine. In situ characterization of the impaired local immune response. **Transplantation** 1986; 41:734-9.
29. Schneider TM, Kupiec-Weglinski JW, Towpik E, Padberg W, Araneda D, Diamantstein T, Strom TB, Tilney NL: Development of suppressor lymphocytes during acute rejection of rat cardiac allografts and preservation of suppression by anti-IL-2-receptor monoclonal antibody. **Transplantation** 1986; 42:191-6.
30. Uhteg LC, Kupiec-Weglinski JW, Rocher LL, Salomon DR, Tilney NL, Carpenter CB: Systemic natural killer activity following cardiac engraftment in the rat: Lack of correlation with graft survival. **Cell. Immunol.** 1986; 100:274-9.
31. Diamantstein T, Volk HD, Tilney NL, Kupiec-Weglinski JW: Specific immunosuppressive therapy by monoclonal anti-IL 2 receptor antibody and its synergistic action with Cyclosporin. **Immunobiol.** 1986; 172: 391-9.
32. Schneider TM, Kupiec-Weglinski JW, Towpik E, Strom TB, Tilney NL: Studies on mechanisms of acute rejection of vascularized organ allografts. **Hum. Immunol.** 1986; 15:320-9.
33. Kupiec-Weglinski JW, Padberg W, Uhteg LC, Ma L, Lord RH, Araneda D, Strom TB, Diamantstein T, Tilney NL: Selective immunosuppression with anti-interleukin 2 receptor-targeted therapy: Helper and suppressor cell activity in rat recipients of cardiac allografts. **Eur. J. Immunol.** 1987; 17:313-9.

34. Padberg WM, Kupiec-Weglinski JW, Lord RHH, Araneda D, Tilney NL: W3/25+ T cells mediate the induction of immunologic unresponsiveness in enhanced rat recipients of cardiac allografts. **J. Immunol.** 1987; 138:3669-74.
35. Padberg WM, Lord RHH, Kupiec-Weglinski JW, Williams JM, Di Stefano R, Thornburg LE, Araneda D, Strom TB, Tilney NL: Two phenotypically distinct populations of T cells have suppressor capabilities simultaneously in the maintenance phase of immunologic enhancement. **J. Immunol.** 1987; 139:1751-7.
36. Padberg WM, Lord RHH, Di Stefano R, Araneda D, Tilney NL, Kupiec-Weglinski JW: Synergy between subtherapeutic doses of Cyclosporine and immunological enhancement in rat recipients of cardiac allografts. **Transplantation** 1988; 45:162-8.
37. Kupiec-Weglinski JW, Austyn JM, Morris PJ: Migration patterns of dendritic cells in the mouse. Traffic from the blood, and T cell- dependent and -independent entry to lymphoid tissues. **J. Exp. Med.** 1988; 167:632-45.
38. Austyn JM, Kupiec-Weglinski JW, Hankins DF, Morris PJ: Migration patterns of dendritic cells in the mouse. Homing to T cell-dependent areas of spleen, and binding within marginal zone. **J. Exp. Med.** 1988; 167:646-51.
39. Di Stefano R, Mouzaki A, Araneda D, Diamantstein T, Tilney NL, Kupiec-Weglinski JW: Anti-interleukin 2 receptor monoclonal antibodies spare phenotypically distinct T suppressor cells in vivo and exert synergistic biological effects. **J. Exp. Med.** 1988; 167:1981-6.
40. Tilney NL, Padberg WM, Lord RHH, Araneda D, Strom TB, Kupiec-Weglinski JW: Synergy between subtherapeutic doses of Cyclosporine and immunological manipulations in rat heart graft recipients. **Transplantation** 1988; 46:122s-8s.
41. Diamantstein T, Eckert R, Volk HD, Kupiec-Weglinski JW: Reversal by interferon-gamma of inhibition of delayed-type hypersensitivity induction by anti-CD4 or anti-interleukin 2 receptor (CD25) monoclonal antibodies. Evidence for the physiological role of CD4+ Th<sub>1</sub>+ subset in mice. **Eur. J. Immunol.** 1988; 18:2101-3.
42. Kupiec-Weglinski JW, Tilney NL, Stunkel KG, Grutzmann R, van der Meide P, Diamantstein T: Agonistic and antagonistic interactions of anti-interleukin 2 receptor monoclonal antibodies in rat recipients of cardiac allografts. **Transplantation** 1989; 47:11-6.
43. Turka LA, Tanaka K, Kupiec-Weglinski JW, Milford EL, Tilney NL, Carpenter CB: In vivo activity of mixed lymphocyte response-generated suppressor cells and ability to prolong cardiac allograft survival in rats. **Transplantation** 1989; 47:388-90.
44. Kupiec-Weglinski JW, Mariani G, Tanaka K, Di Stefano R, Stunkel KG, Diamantstein T, Tilney NL: Biodistribution of anti-interleukin 2 receptor monoclonal antibodies correlates with their therapeutic efficacy following transplantation. **Cell. Immunol.** 1989; 123:148-57.
45. Tanaka K, Hancock WW, Osawa H, Stunkel KG, Alberghini TV, Diamantstein T, Tilney NL, Kupiec-Weglinski JW: Mechanism of action of anti-IL-2R monoclonal antibodies. ART-18 prolongs cardiac allograft survival in rats by elimination of IL-2R<sup>+</sup> mononuclear cells. **J. Immunol.** 1989; 143:2873-9.
46. Hancock WW, Di Stefano R, Braun P, Schweizer RT, Tilney NL, Kupiec-Weglinski JW: Cyclosporine and anti-interleukin 2 receptor mAb therapy suppress accelerated rejection of rat cardiac allografts through different effector mechanisms. **Transplantation** 1990; 49:416-21.
47. Ueda H, Hancock WW, Cheung YC, Tanaka K, Kupiec-Weglinski JW, Tilney NL: Differential effects of interleukin 2 receptor-targeted therapy on heart and kidney allografts in rats. Depression of effectiveness of ART-18 monoclonal antibody treatment by uremia. **Transplantation** 1990; 49:1124-9.
48. Tanaka K, Turka LA, Kupiec-Weglinski JW, Milford EL, Ueda H, Diamantstein T, Carpenter CB, Tilney NL: Evidence that monoclonal antibodies against the 55kD subunit of the rat IL-2 receptor do not inhibit the development of suppressor cells generated in mixed lymphocyte culture. **Transplantation** 1990; 50:125-31.

49. Ueda H, Hancock WW, Cheung YC, Diamantstein T, Tilney NL, Kupiec-Weglinski JW: The mechanism of synergistic interaction between anti-interleukin 2 receptor monoclonal antibody and cyclosporine therapy in rat recipients of organ allografts. **Transplantation** 1990; 50:545-50.
50. Tanaka K, Tilney NL, Stunkel KG, Hancock WW, Diamantstein T, Kupiec-Weglinski JW: Pretreatment with cyclosporine A and anti-interleukin 2 receptor antibody abrogates anti-idiotypic response in rat recipients of cardiac allografts. **Proc. Natl. Acad. Sci. USA** 1990; 87:7375-9.
51. Sablinski T, Sayegh MH, Hancock WW, Kut JP, Kwok CA, Milford EL, Tilney NL, Kupiec-Weglinski JW: Differential role of CD4<sup>+</sup> cells in the sensitization and effector phases of accelerated graft rejection. **Transplantation** 1991; 51:226-31.
52. Sayegh MH, Sablinski T, Tanaka K, Kut JP, Kwok CA, Tilney NL, Kupiec-Weglinski JW, Milford EL: Effects of BWH-4 anti-CD4 monoclonal antibody on rat vascularized cardiac allografts before and after engraftment. **Transplantation** 1991; 51:296-9.
53. Kupiec-Weglinski JW, Sablinski T, Hancock WW, Di Stefano R, Mariani G, Mix CT, Tilney NL: Modulation of accelerated rejection of cardiac allografts in sensitized rats by anti-interleukin 2 receptor monoclonal antibody and cyclosporine therapy. **Transplantation** 1991; 51:300-5.
54. Kupiec-Weglinski JW, de Sousa M: Lymphocyte traffic is modified in vivo by anti-laminin antibody. **Immunology** 1991; 72:312-3.
55. De Sousa M, Tilney NL, Kupiec-Weglinski JW: Recognition of self within self: specific lymphocyte positioning and the extracellular matrix. **Immunol. Today** 1991; 12:262-6.
56. Ueda H, Cheung Y-C, Masetti P, Diaco M, McCarter M, Kupiec-Weglinski JW, Tilney NL: Synergy between cyclosporine and anti-IL-2 receptor monoclonal antibodies in rats. Functional studies of heart and kidney allografts. **Transplantation** 1991; 52:437-42.
57. Sablinski T, Sayegh MH, Kut JP, Tilney NL, Milford EL, Kupiec-Weglinski JW: The importance of targeting the CD4<sup>+</sup> T cell subset at the time of antigenic challenge for induction of prolonged vascularized allograft survival. **Transplantation** 1992; 53:219-21.
58. Papp I, Wieder KJ, Sablinski T, O'Connell PJ, Milford EL, Strom TB, Kupiec-Weglinski JW: Evidence for functional heterogeneity of rat CD4<sup>+</sup> T cells in vivo. Differential expression of IL-2 and IL-4 mRNA in recipients of cardiac allografts. **J. Immunol.** 1992; 148:1308-14.
59. Hancock WW, Sayegh MH, Sablinski T, Kut JP, Kupiec-Weglinski JW, Milford EL: Blocking of mononuclear cell accumulation, cytokine production, and endothelial activation within rat cardiac allografts by CD4 monoclonal antibody therapy. **Transplantation** 1992; 53:1276-80.
60. Sablinski T, Sayegh MH, Kut JP, Milford EL, Tilney NL, Kupiec-Weglinski JW: Evidence that therapeutic strategies targeted at CD4<sup>+</sup> cells modulate accelerated rejection of cardiac allografts in sensitized rats by different mechanisms. **Transplantation** 1992; 54:292-6.
61. Tanaka K, Tilney NL, Kupiec-Weglinski JW: Maturing thymocytes in accelerated rejection of cardiac allografts in presensitized rats. **Transplantation** 1992; 54:515-9.
62. Schmidbauer G, Hancock WW, Badger AM, Kupiec-Weglinski JW: Induction of nonspecific x-irradiation-resistant suppressor cell activity in vivo and prolongation of vascularized allograft survival by SK&F 105685, a novel immunomodulatory azaspirane. **Transplantation** 1993; 55:1236-43.
63. Wieder KJ, Hancock WW, Schmidbauer G, Corpier CL, Wieder I, Kobzik L, Strom TB, Kupiec-Weglinski JW: Rapamycin treatment depresses intragraft expression of KC/MIP-2, granzyme B, and IFN- $\gamma$  in rat recipients of cardiac allografts. **J. Immunol.** 1993; 151:1158-66.

64. Kupiec-Weglinski JW, Wasowska B, Papp I, Schmidbauer G, Sayegh MH, Baldwin WM III, Wieder KJ, Hancock WW: CD4 mAb therapy modulates alloantibody production and intracardiac graft deposition in association with selective inhibition of Th1 lymphokines. **J. Immunol.** 1993; 151:5053-61.
65. Whitley WD, Hancock WW, Kupiec-Weglinski JW, de Sousa M, Tilney NL: Iron chelation suppresses mononuclear cell activation, modifies lymphocyte migration patterns, and prolongs rat cardiac allograft survival in rats. **Transplantation** 1993; 56:1182-8.
66. Coito AJ, Binder J, de Sousa M, Kupiec-Weglinski JW: The expression of extracellular matrix proteins during accelerated rejection of cardiac allografts in sensitized rats. **Transplantation** 1994; 57:599-605.
67. Schmidbauer G, Hancock WW, Wasowska B, Badger AM, Kupiec-Weglinski JW: Abrogation by Rapamycin of accelerated rejection in sensitized rats by inhibition of alloantibody responses and selective suppression of intragraft mononuclear/endothelial cell activation, cytokine production, and cell adhesion. **Transplantation** 1994; 57:933-41.
68. Binder J, Sayegh MH, Watschinger B, Hancock WW, Kupiec-Weglinski JW: Intrathymic injection of donor-specific x-irradiation-sensitive spleen cells abrogates accelerated rejection of cardiac allografts in sensitized rats. **Transplantation** 1994; 58:80-6.
69. Binder J, Mishina EV, Jusko WJ, Kupiec-Weglinski JW: Prolongation of cardiac allograft survival in rats by liposome-encapsulated methylprednisolone. **Transplantation** 1994; 58:633-5.
70. Mishina EV, Binder J, Kupiec-Weglinski JW, Jusko WJ: Effect of liposomal methylprednisolone on heart allograft survival and immune function in rats. **J. Pharmacol. Exp. Ther.** 1994; 271:868-74.
71. Heidecke CD, Hancock WW, Jakobs F, Zantl N, Kurrle R, Westerholt S, Sewczik T, Deusch K, Kupiec-Weglinski JW:  $\alpha/\beta$ -T cell receptor-directed therapy in rat cardiac allograft recipients: Treatment prior to alloantigen exposure prevents sensitization and abrogates accelerated rejection. **Transplantation** 1995; 59:78-84.
72. Binder J, Hancock WW, Watschinger B, Wasowska B, Sayegh MH, Kupiec-Weglinski JW: The alloantibody network following intrathymic immunomodulation of sensitized rat recipients of cardiac allografts. **Transplantation** 1995; 59:590-7.
73. Binder J, Graser E, Hancock WW, Wasowska B, Sayegh MH, Volk HD, Kupiec-Weglinski JW: Downregulation of intragraft IFN- $\gamma$  expression correlates with increased IgG1 alloantibody response following intrathymic immunomodulation of sensitized rat recipients. **Transplantation** 1995; 60:1516-24.
74. Coito AJ, Binder J, Brown LF, de Sousa M, Van De Water L, Kupiec-Weglinski JW: Anti-TNF- $\alpha$  treatment down-regulates the expression of fibronectin and decreases cellular infiltration of cardiac allografts in rats. **J. Immunol.** 1995; 154:2949-58.
75. Wasowska B, Wieder KJ, Hancock WW, Zheng XX, Berse B, Binder J, Strom TB, Kupiec-Weglinski JW: Cytokine and alloantibody networks in long-term cardiac allografts in rat recipients treated with rapamycin. **J. Immunol.** 1996; 156:395-404.
76. Heidecke CD, Zantl N, Maier S, Varzaru A, Hager B, Varzaru A, Kupiec-Weglinski JW, Hancock WW: Induction of long-term rat renal allograft survival by pretransplant T cell receptor  $\alpha/\beta$ -targeted therapy. **Transplantation** 1996; 61:336-9.
77. Binder J, Lehmann M, Graser E, Hancock WW, Watschinger B, Onodera K, Sayegh MH, Volk HD, Kupiec-Weglinski JW: The effects of nondepleting CD4 targeted therapy in presensitized rat recipients of cardiac allografts. **Transplantation** 1996; 61:804-11.
78. Heidecke CD, Hancock WW, Westerholt S, Sewczik T, Jakobs F, Zantl N, Varzaru A, Siegling A, Kurrle R, Deusch K, Volk HD, Kupiec-Weglinski JW:  $\alpha/\beta$ -T cell receptor-directed therapy in rat allograft recipients. Long-term survival of cardiac allografts after pretreatment with R73 mAb is associated with upregulation of Th2-type cytokines. **Transplantation** 1996; 61:948-56.

79. Onodera K, Lehmann M, Akalin E, Volk HD, Sayegh MH, Kupiec-Weglinski JW: Induction of "infectious" tolerance to MHC-incompatible cardiac allografts in CD4 mAb-treated sensitized rat recipients. **J. Immunol.** 1996; **157**:1944-50.
80. Onodera K, Hancock WW, Graser E, Lehmann M, Sayegh MH, Strom TB, Volk HD, Kupiec-Weglinski JW: Type 2 helper T cell-type cytokines and the development of "infectious" tolerance in rat cardiac allograft recipients. **J. Immunol.** 1997; **158**:1572-81.
81. Onodera K, Chandraker A, Schaub M, Stadlbauer THW, Korom S, Peach R, Linsley PS, Sayegh MH, Kupiec-Weglinski JW: CD28-B7 T cell costimulatory blockade by CTLA4Ig in sensitized rat recipients: Induction of transplantation tolerance in association with depressed cell mediated and humoral immune responses. **J. Immunol.** 1997; **159**:1711-7.
82. Coito AJ, Brown LF, Peters JH, Kupiec-Weglinski JW, Van De Water L: Expression of fibronectin splicing variants in organ transplantation: A differential pattern between rat cardiac allografts and isografts. **Am. J. Pathol.** 1997; **150**:1757-72.
83. Korom S, De Meester I, Stadlbauer THW, Chandraker A, Schaub M, Sayegh MH, Belyaev A, Haemers A, Scharpe S, Kupiec-Weglinski JW: Inhibition of CD26/Dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. **Transplantation** 1997; **63**:1495-500.
84. Lehmann M, Graser E, Risch K, Hancock WW, Muller A, Kuttler B, Hahn HJ, Kupiec-Weglinski JW, Brock J, Volk HD: Anti-CD4 monoclonal antibody-induced allograft tolerance in rats despite persistence of donor-reactive T cells. **Transplantation** 1997; **64**:1181-7.
85. Stadlbauer THW, Schaub M, Korom S, Onodera K, Sayegh MH, Kupiec-Weglinski JW: CD28-B7 T-cell co-stimulatory blockade potentiates the effects of intrathymic immunomodulation in sensitized graft recipients. **Transplantation** 1997; **64**:1816-22.
86. Coito AJ, Korom S, Graser E, Volk HD, Van De Water L, Kupiec-Weglinski JW: Blockade of very late antigen-4 integrin binding to fibronectin in allograft recipients. I. Treatment with connecting segment-1 peptides prevents acute rejection by suppressing intragraft mononuclear cell accumulation, endothelial activation, and cytokine expression. **Transplantation** 1998; **65**:699-706.
87. Korom S, Hancock WW, Coito AJ, Kupiec-Weglinski JW: Blockade of very late antigen-4 integrin binding to fibronectin in allograft recipients. II. Treatment with CS1 peptides prevents chronic rejection by attenuating arteriosclerotic development and suppressing intragraft T cell and macrophage activation. **Transplantation** 1998; **65**:854-9.
88. Heidecke CD, Zantl N, Maier SD, Sewczik T, Westerholt S, Jakobs F, Westerholt A, Hancock WW, Kupiec-Weglinski JW: Importance of T cells to accelerated rejection and acceptance of renal allografts in sensitized rat recipients. **Transplantation** 1998; **66**:1354-61.
89. Onodera K, Volk HD, Ritter T, Kupiec-Weglinski JW: Thymus requirement and antigen dependency in the "infectious" tolerance pathway in transplant recipients. **J. Immunol.** 1998; **160**:5765-72.
90. Dulkanchainun TS, Goss JA, Imagawa DK, Shaw GD, Anselmo DM, Kaldas F, Wang T, Zhao D, Busuttil AA, Kato H, Murray NGB, Kupiec-Weglinski JW, Busuttil RW: The reduction of hepatic ischemia/reperfusion injury by a soluble P-selectin glycoprotein ligand-1. **Ann. Surg.** 1998; **227**:832-40.
91. Onodera K, Chandraker A, Volk HD, Ritter T, Lehmann M, Kato H, Sayegh MH, Kupiec-Weglinski JW: Distinct tolerance pathways in sensitized allograft recipients after selective blockade of activation signal 1 or signal 2. **Transplantation** 1999; **68**:288-93.
92. Reemtsen BL, Kato H, Wang TS, Busuttil RW, Kupiec-Weglinski JW, Goss JA: Intrathymic immunomodulation and the "infectious" tolerance pathway in allograft recipients. **J. Surg. Res.** 1999; **84**:1-7.

93. Amersi F, Buelow R, Kato H, Ke B, Coito AJ, Shen XD, Zhao D, Zaky J, Melenik J, Lassman CR, Kolls JK, Alam J, Ritter T, Volk HD, Farmer DG, Ghobrial RM, Busuttil RW, Kupiec-Weglinski JW: Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injury. **J. Clin. Invest.** 1999; 104:1631-9.
94. Kupiec-Weglinski JW: CD25-targeted therapy revisited. **Transplantation** 2000; 69:328-30.
95. Ke B, Coito AJ, Kato H, Zhai Y, Wang T, Seu P, Busuttil RW, Kupiec-Weglinski JW: Fas ligand gene transfer prolongs rat renal allograft survival and downregulates anti-apoptotic Bag-1 in parallel with enhanced Th2-type cytokine expression. **Transplantation** 2000; 69:1690-4.
96. Ke B, Ritter T, Kato H, Zhai Y, Li J, Lehmann M, Busuttil RW, Volk HD, Kupiec-Weglinski JW: Regulatory cells potentiate the efficacy of IL-4 gene therapy by upregulating Th2-dependent expression of protective molecules in the infectious tolerance pathway in transplant recipients. **J. Immunol.** 2000; 164:5739-45.
97. Coito AJ, Kato H, Onodera K, Busuttil RW, Kupiec-Weglinski JW: Fibronectin –  $\alpha 4\beta 1$  integrin interactions regulate Th1 cytokine network in tolerant cardiac allograft recipients. **Am. J. Pathol.** 2000; 157:1207-18
98. Stadlbauer THW, Schaub M, Magee CC, Kupiec-Weglinski JW, Sayegh MH: Intrathymic immunomodulation in sensitized rat recipients of cardiac allografts: Requirements for allorecognition pathways. **J. Heart Lung Transplant.** 2000; 19:566-75.
99. Hammer MH, Zhai Y, Katori M, Ritter T, Volk HD, Coito A, Kupiec-Weglinski JW: Homing of in vitro-generated donor antigen-reactive CD4<sup>+</sup> T lymphocytes to renal allografts is  $\alpha 4\beta 1$  but not  $\alpha L\beta 2$  integrin dependent. **J. Immunol.** 2001; 166:596-601.
100. Kato H, Amersi F, Buelow R, Melinek J, Coito AJ, Ke B, Busuttil RW, Kupiec-Weglinski JW: Heme oxygenase-1 overexpression protects rat livers from ischemia/reperfusion injury with extended cold preservation. **Am. J. Transplant.** 2001; 1:121-8.
101. Amersi F, Dulkanchainun T, Nelson SK, Farmer DG, Kato H, Zaky J, Melinek J, Shaw GD, Kupiec-Weglinski JW, Horwitz LD, Horwitz MA, Busuttil RW: Novel iron chelator in combination with a P-selectin antagonist prevents ischemia/reperfusion injury in a rat liver model. **Transplantation** 2001; 71:112-8.
102. Wasowska BA, Zheng, XX, Strom TB, Kupiec-Weglinski JW: Adjunctive rapamycin and CsA treatment inhibits monocyte/macrophage associated cytokines/chemokines in sensitized cardiac graft recipients. **Transplantation** 2001; 71:1179-83.
103. Zhai Y, Li J, Hammer M, Busuttil R, Volk HD, Kupiec-Weglinski JW: Evidence of T cell clonality in the infectious tolerance pathway: Implications toward identification of regulatory T cells. **Transplantation** 2001; 71:1701-8 [Rapid Communication].
104. Coito AJ, Kupiec-Weglinski JW: Extracellular matrix-mediated interactions in organ transplantation. **Transplantation** 2001; 72:173.
105. Zhai Y, Shen XD, Lehmann M, Busuttil RW, Volk HD, Kupiec-Weglinski JW: T cell subsets and in vitro immune regulation in the "infectious" transplantation tolerance. **J. Immunol.** 2001; 167:4814-20.
106. Singer JS, Mhoyan A, Fishbein M, ShenXD, Gao F, Reemtsen B, Zhao D, Amersi F, Coito AJ, Busuttil RW, Kupiec-Weglinski JW, Ghobrial RM: Treatment with allochimeric class I MHC molecules inhibits chronic rejection and attenuates alloantibody responses in rat cardiac allograft recipients. **Transplantation** 2001; 72:1408-16.
107. Coito AJ, Shaw GD, Li J, Ke B, Ma J, Busuttil RW, Kupiec-Weglinski JW: Selectin-mediated interactions regulate cytokine networks and macrophage heme oxygenase-1 induction in cardiac allograft recipients. **Lab. Invest.** 2002; 82:61-70.
108. Sawitzki B, Lehmann M, Vogt K, Risch K, Brock J, Kupiec-Weglinski JW, Volk HD: Bag-1 upregulation in anti-CD4 mAb treated allo-activated T cells confers resistance to apoptosis. **Eur. J. Immunol.** 2002; 32:800-9.

109. Sawitzki B, Lehmann M, Vogt K, Seifert M, Risch K, Brock J, Kupiec-Weglinski JW, Volk HD: Bag-1 up-regulation in anti-CD4 mAb treated allo-activated T cell confers resistance to activation-induced cell death (AICD). **Transplant. Immun.** 2002; **9:83-91**.
110. Amersi F, Shen XD, Anselmo D, Melinek J, Iyer S, Southard DJ, Katori M, Volk HD, Busuttil RW, Buelow R, Kupiec-Weglinski JW: Ex-vivo exposure to carbon monoxide prevents hepatic ischemia/reperfusion injury through p38 MAP kinase pathway. **Hepatology** 2002; **35:815-23**.
111. Katori M, Buelow R, Ke B, Ma J, Coito AJ, Busuttil RW, Kupiec-Weglinski JW: Heme oxygenase1 overexpression protects rat hearts from cold ischemia/reperfusion injury via anti-apoptotic pathway. **Transplantation** 2002; **73:287-92**.
112. Hancock WW, Gao W, Shemmeri N, Shen X-D, Gao F, Busuttil RW, Zhai Y, Kupiec-Weglinski JW: Immunopathogenesis of accelerated allograft rejection in sensitized recipients: Humoral and non-humoral mechanisms. **Transplantation** 2002; **73:1392-7 [Rapid Communication]**.
113. Coito A, Buelow R, Shen XD, Amersi F, Moore C, Volk HD, Busuttil RW, Kupiec-Weglinski JW: Heme oxygenase-1 gene transfer inhibits inducible nitric oxide synthase expression and protects genetically fat Zucker rat livers from ischemia/reperfusion injury. **Transplantation** 2002; **74:96-102**.
114. Shen XD, Ke B, Zhai Y, Amersi F, Gao F, Melinek J, Anselmo D, Busuttil RW, Kupiec-Weglinski JW: CD154-CD40 T cell costimulation pathway is required in the mechanism of hepatic ischemia/reperfusion injury and its blockade facilitates and depends on heme-oxygenase-1 mediated cytoprotection. **Transplantation** 2002; **74:315-9**.
115. Amersi F, Farmer DG, Shaw GD, Kato H, Coito AJ, Kaldas F, Zhao D, Lassman CR, Melinek J, Ma J, Volk HD, Kupiec-Weglinski JW, Busuttil RW: P-selectin glycoprotein ligand-1 (rPSGL-Ig) mediated blockade of CD62 selectin molecules protects steatotic liver grafts from ischemia/reperfusion injury. **Am. J. Transplant.** 2002; **2:600-8**.
116. Anselmo DM, Amersi FF, Shen X-D, Gao F, Katori M, Lassman C, Ke B, Coito A, Ma J, Brinkmann V, Busuttil RW, Kupiec-Weglinski JW, Farmer DG: FTY720 pretreatment reduces warm hepatic ischemia reperfusion injury through inhibition of T-lymphocyte infiltration. **Am. J. Transplant.** 2002; **2:843-9**.
117. Amersi F, Nelson SK, Shen XD, Kato H, Melinek J, Kupiec-Weglinski JW, Horwitz LD, Busuttil RW, Horwitz MA: Bucillamine, a thiol anti-oxidant, prevents transplantation-associated reperfusion injury in normal and fatty rat livers. **Proc. Natl. Acad. Sci. USA** 2002; **99:8915-20**.
118. Ke B, Buelow R, Shen XD, Melinek J, Amersi F, Gao F, Ritter T, Volk HD, Busuttil RW, Kupiec-Weglinski JW: Heme oxygenase-1 gene transfer prevents CD95/Fas -mediated apoptosis and improves liver allograft survival via carbon monoxide signaling pathway. **Hum. Gene Ther.** 2002; **13:1189-99**.
119. Sawitzki B, Amersi F, Ritter T, Fisser M, Shen XD, Busuttil RW, Volk HD, Kupiec-Weglinski JW: Upregulation of Bag-1 by ex-vivo gene transfer protects rat livers from ischemia/reperfusion injury. **Hum. Gene Ther.** 2002; **13:1495-1504**.
120. Ke B, Shen XD, Gao F, Zhai Y, Busuttil RW, Volk HD, Kupiec-Weglinski JW: Heme oxygenase 1 mediates the immunomodulatory and antiapoptotic effects of interleukin 13 gene therapy in vivo and in vitro. **Hum. Gene Ther.** 2002; **13:1845-57**.
121. Zhai Y, Shen XD, Gao F, Coito AJ, Wasowska BA, Salama AD, Schmitt I, Busuttil RW, Sayegh MH, Kupiec-Weglinski JW: CD154-CD40 T cell costimulation pathway is required for host sensitization of CD8+ T cells by skin grafts via direct antigen presentation. **J. Immunol.** 2002; **169:1270-6**.
122. Zhai Y, Gao F, Meng L, Busuttil RW, Kupiec-Weglinski JW: CD154 blockade fails to prevent activation of alloreactive primed memory CD8+ T cells: Therapeutic implications for sensitized transplant recipients. **J. Immunol.** 2002; **169:4667-73**.
123. Blydt-Hansen TD, Katori M, Lassman C, Ke B, Coito AJ, Iyer S, Buelow R, Ettenger R, Busuttil RW, Kupiec-Weglinski JW: Gene transfer-induced local heme oxygenase-1 overexpression protects rat kidney transplants from ischemia/ reperfusion injury. **J. Am. Soc. Nephrol.** 2003; **14:745-54**.



124. Shen XD, Ke B, Zhai Y, Gao F, Anselmo D, Lassman CR, Busuttil RW, Kupiec-Weglinski JW: Stat4 and Stat6 signaling in hepatic ischemia/reperfusion injury: HO-1 dependence of STAT4 disruption-mediated cytoprotection. *Hepatol* 2003; 37:296-303.
125. Zhai Y, Meng L, Busuttil RW, Sayegh MH, Kupiec-Weglinski JW: Activation of alloreactive CD8+ T cells operates via CD4-dependent and CD4-independent mechanisms and is CD154 blockade-sensitive. *J. Immunol.* 2003; 75:514-21.
126. Zhai Y, Kupiec-Weglinski JW: T-cell receptor  $\beta$ -chain usage in directly activated alloreactive CD4+ T cells: Unrestricted V $\beta$  gene usage with CDR3 size limitations. *Transplantation* 2003; 75:514-21.
127. Semiletova N, Shen XD, Fishbein MC, Gao F, Slomovitz SJ, Jiao Q, Mukherjee K, Busuttil RW, Kupiec-Weglinski JW, Ghobrial MR. Postransplant administration of allochimeric MHC class I molecules induces true transplantation tolerance. *Transplantation* 2003; 75:550-2.
128. Ke B, Shen XD, Lassman CR, Gao F, Katori M, Busuttil RW, Kupiec-Weglinski JW: IL-13 gene transfer protects rat livers from antigen-independent injury induced by ischemia and reperfusion. *Transplantation* 2003; 75: 1118-23.
129. Ke B, Shen XD, Lassman CR, Gao F, Katori M, Busuttil RW, Kupiec-Weglinski JW: Cytoprotective and anti-apoptotic effects of IL-13 in liver ischemia/reperfusion injury are heme oxygenase-1 dependent. *Am. J. Transplant.* 2003; 3:1076-82.
130. Amersi F, Shen HD, Moore C, Melinek J, Busuttil RW, Kupiec-Weglinski JW, Coito AJ. Fibronectin -  $\alpha 4\beta 1$  integrin mediated blockade protects steatotic liver grafts from ischemia/reperfusion injury. *Am. J. Pathol.* 2003; 162:1229-39.
131. Araujo JA, Meng L, Tward AD, Hancock WW, Zhai Y, Lee A, Ishikawa, K, Iyer S, Buelow R, Busuttil RW, Shih DM, Lulis AJ, Kupiec-Weglinski JW: Systemic rather than local heme oxygenase-1 overexpression improves cardiac allograft outcomes in a new transgenic mouse. *J. Immunol.* 2003; 171:1572-80.
132. Berberat PO, Katori M, Kaczmarek E, Anselmo D, Lassman C, Ke B, Shen X, Busuttil RW, Yamashita K, Otterbein LE, Brouard S, Tobiasch E, Bach FH, Kupiec-Weglinski JW, Soares MP: Heavy chain ferritin acts as an anti-apoptotic gene that protects livers from ischemia reperfusion injury. *FASEB J.* 2003; 17:1724-6.
133. Zhai Y, Meng L, Busuttil RW, Kupiec-Weglinski JW: Direct evidence of alloreactive CD8+ T cell inhibition by CD4+ T regulatory cells in maintaining transplantation tolerance. *J. Immunol.* (In press).
134. Ke B, Shen XD, Gao F, Busuttil RW, Lowenstein P, Kupiec-Weglinski JW: Gene therapy for liver transplantation using adenoviral vectors: CD40-CD154 blockade by gene transfer of CD40lg protects rat livers from cold ischemia and reperfusion injury. *Molec. Ther.* (In press).
135. Zhai Y, Shen X, Gao F, O'Connell, R, Hancock WW, Busuttil RW, Cheng G, Kupiec-Weglinski JW: IP-10 links TLR4 activation and T cell responses: type-1 IFN receptor-dependent signaling pathway in liver ischemia/reperfusion injury. (submitted).
136. Anselmo DM, Katori M, Amersi FF, Shen XD, Ke B, Lassman C, Kaldas M, Clozel M, Busuttil RW, Kupiec-Weglinski JW, Farmer DG. Endothelin receptor blockade with tezosentan attenuates hepatic injury in models of both warm and cold ischemia and reperfusion injury. (submitted).
137. Semiletova N, Mhoyan A, Shen XD, Fishbein MC, Gao F, Zhao D, Reemtsen BL, Stepkowski SM, Busuttil RW, Kupiec-Weglinski JW, Ghobrial MR. Class I allochimeric presentation of composite immunogenic and self epitopes induces tolerance to genetically diverse rat strains. (submitted).
138. Shen XD, Ke B, Zhai Y, Gao F, Busuttil RW, Cheng G, Kupiec-Weglinski JW: Toll-like receptor 4 signaling is critical in the mechanism of hepatic ischemia/reperfusion injury. (submitted).
139. Ke B, Shen XD, Gao F, Busuttil RW, Kupiec-Weglinski JW: Stat6 transcription is required for IL-13 cytoprotection and prevention of inflammatory injury induced by ischemia and reperfusion. (submitted).

## REVIEW ARTICLES:

1. Kupiec-Weglinski JW, Tilney NL: Heart transplantation in the rat: Mechanisms of rejection, and graft prolongation. **Heart Transplant. 1982; 1:93-101.**
2. Kupiec-Weglinski JW, Tilney NL: Immunobiology of acute allograft rejection. **J. Clin. Surg. 1982; 1:403-13.**
3. Tilney NL, Kupiec-Weglinski JW, Heidecke CD, Lear PA, Strom TB: Mechanisms of rejection and prolongation of vascularized organ allografts. **Immunol. Rev. 1984; 77:185-216.**
4. Araujo JL, Towpik E, Kupiec-Weglinski JW, Tilney NL: Cyclosporine: Experimental studies and clinical applications in organ transplantation, (In Spanish). **Rev. Invest. Clin. 1984; 36:367-76.**
5. Towpik E, Araujo JL, Kupiec-Weglinski JW, Tilney NL: Cyclosporine A - A new immunosuppressive drug. (In Polish). **P. I. Tyg. Lek. 1984; 38:1735-9.**
6. Towpik E, Kupiec-Weglinski JW, Tilney NL: The first successful transplantation of kidney - already belonging to the history of medicine. (In Polish). **Wiad. Lek. 1985; 38:1751-8.**
7. Tilney NL, Kupiec-Weglinski JW: Acute host responses to organ allografts. **Clin. Immunol. Newsletter 1986; 7:102-5.**
8. Abbud-Filho M, Loertscher R, Kupiec-Weglinski JW, Tilney NL, Strom TB: Cyclosporine in transplantation: A review of clinical and experimental studies. **Mem. Inst. Oswaldo Cruz, Rio de Janeiro. 1987; 82: 95-100.**
9. Tilney NL, Strom TB, Kupiec-Weglinski JW: Humoral and cellular mechanisms in acute graft injury. **J. Pediat. 1987; 111:1000-3.**
10. Padberg WM, Schwemmler K, Dobroschke J, Kupiec-Weglinski JW, Tilney NL: Immunosuppressive therapy in organ transplantation. (In German). **Dtsch. med. Wschr. 1987; 112:1670-4.**
11. Kupiec-Weglinski JW, Diamantstein T, Tilney NL: Interleukin 2 receptor targeted therapy - rationale and applications in organ transplantation. **Transplantation 1988; 46:785-92.**
12. Austyn JM, Kupiec-Weglinski JW, Morris PJ: Migration patterns of dendritic cells in the mouse. **Adv. Exp. Med. Biol. 1988; 237:583-9.**
13. Kupiec-Weglinski JW, Strom TB, Diamantstein T, Tilney NL: Interleukin 2 receptor targeted therapy: A new approach to combat allograft rejection. **Nefrologia 1988; 8:303-10.**
14. Kupiec-Weglinski JW, Tilney NL: Lymphocyte migration patterns in organ allograft recipients. **Immunol. Rev. 1989; 108:63-82.**
15. Diamantstein T, Kupiec-Weglinski JW, Strom TB, Tilney NL: Current stage of interleukin 2 receptor targeted therapy. **Exp. Clin. Endocrinol. 1989; 93:114-24.**
16. Tanaka K, Kupiec-Weglinski JW, Tilney NL: Suppressor T cell (Ts) sparing effect. (In Japanese). **Jpn. J. Clin. Immunol. 1989; 12(5):446-8.**
17. Whitley D, Kupiec-Weglinski JW, Tilney NL: Antibody-mediated rejection of organ grafts. **Curr. Opin. Immunol. 1990; 2:864-9.**
18. De Sousa M, da Silva MT, Kupiec-Weglinski JW: Collagen, the circulation and positioning of lymphocytes: A unifying clue? **Scand. J. Immunol. 1990; 31:249-56.**
19. Sablinski T, Hancock WW, Tilney NL, Kupiec-Weglinski JW: Biology of vascularized organ allograft rejection in sensitized recipients. **Transplant. Rev. 1990; 4:108-20.**
20. Tilney NL, Kupiec-Weglinski JW: The immunobiology of acute transplant rejection. **Ann. Surg. 1991; 214:98-106.**

21. Kupiec-Weglinski JW, Di Stefano R, Sablinski T, Hancock WW, Tilney NL: CD25 and CD4 targeted immunosuppressive therapy in experimental organ transplantation. **Minerva Chir.** 1991; 46 (Suppl. 1):71-4.
22. Tilney NL, Whitley WD, Diamond JR, Kupiec-Weglinski JW, Adams DH: Chronic rejection - an undefined conundrum. **Transplantation** 1991; 52:389-98.
23. Sablinski T, Hancock WW, Tilney NL, Kupiec-Weglinski JW: CD4 monoclonal antibodies in organ transplantation - a review of progress. **Transplantation** 1991; 52:579-89.
24. Kupiec-Weglinski JW, Strom TB: Interleukin 2 receptor-targeted immunosuppressive therapy in organ transplantation. **Drug News Perspect.** 1991; 4:601-7.
25. De Sousa M, Coito AJ, Schmidbauer GS, Kupiec-Weglinski JW: Ecotaxis and the extracellular matrix: "a splendid net always catching more than it probably intended". **Ciencia e Cultura** 1992; 44:234-8.
26. Sablinski T, Wasik MA, Tilney NL, Kupiec-Weglinski JW: Interleukin-2 receptor-targeted immunotherapy - update and an attempt at synthesis. (In Polish). **Post. Hig. Med. Dosw.** 1992; 46: 275-85.
27. Kupiec-Weglinski JW, Heemann UW, Coito AJ, Tullius SG, Tilney NL, de Sousa M: Adhesion molecule interaction with extracellular matrix. **Exp. Nephrol.** 1993; 1:78-82.
28. Binder J, Kupiec-Weglinski JW: CD4 targeted therapy in organ graft recipients. **Transplant. Sci.** 1993; 3:210-6.
29. Heemann UW, Tullius SG, Kupiec-Weglinski JW, Tilney NL: Early events in acute allograft rejection: leukocyte/endothelial cell interactions. **Clin. Transplantation** 1993; 7:82-9.
30. Heeman UW, Tullius SG, Azuma H, Kupiec-Weglinsky J, Tilney NL: Adhesion molecules and transplantation. **Ann. Surg.** 1994; 219:4-12.
31. Coito AJ, de Sousa M, Kupiec-Weglinski JW: The role of cellular and extracellular matrix adhesion proteins in organ transplantation. **Cell Adhes. Commun.** 1994; 2:249-55.
32. Binder J, Schmidbauer G, Hancock WW, Tullius SG, Sayegh MH, Kupiec-Weglinski JW: Thymus-Injektion von Donormilzzellen verhindert die akzelerierte Transplantatabstossung in sensibilisierten Ratten (In German). **Langenbecks Arch. Chir. Suppl. Chir. Forum** 1994; 325-9.
33. Kupiec-Weglinski JW, Coito A, Gorski A, de Sousa M: Lymphocyte migration and tissue positioning in allograft recipients: The role played by extracellular matrix proteins. **Transplant. Rev.** 1995; 9:29-40.
34. Gorski A, Kupiec-Weglinski JW: Extracellular matrix proteins, regulators of T-cell functions in healthy and diseased individuals. **Clin. Diagn. Lab. Immunol.** 1995; 2:646-51.
35. Kupiec-Weglinski JW: Graft rejection in sensitized recipients. **Annals of Transplantation** 1996; 1:34-40.
36. Coito AJ, Kupiec-Weglinski JW: Extracellular matrix proteins: bystanders or active participants in the allograft rejection cascade? **Annals of Transplantation** 1996; 3:14-8.
37. Stadlbauer THW, Kupiec-Weglinski JW: Immunobiology of sensitization in transplant recipients. **Am. J. Med. Sci.** 1997; 313:268-74.
38. Kupiec-Weglinski JW, Gorski A: Role of extracellular matrix proteins in organ transplantation. **Arch. Immun. I. et Ther. Exp.** 1997; 45:7-13.
39. Ghobrial RM, Busuttil RW, Kupiec-Weglinski JW: Monoclonal antibodies. **Curr. Opin. Organ Transplant.** 1997; 2:82-8.
40. Korom S, De Meester I, Stadlbauer THW, Chandraker A, Schaub M, Schwemmler K, Kupiec-Weglinski JW: Auswirkung der spezifischen CD26/Dipeptidylpeptidase IV (DPP IV)-Inhibition auf die akute Transplantatabstossung

- und die Immunantwort in Allotransplantatempfängern. (In German). **Langenbecks Arch. Chir. Suppl. Chir. F** rum 1997; 191-4.
41. Stadlbauer THW, Schaub M, Korom S, Sayegh MH, Kupiec-Weglinski JW: Intrathymale Immunomodulation ermöglicht ein therapeutisches Fenster zur systemischen Applikation von CTLA4Ig in einem Modell der akzelerierter Abstoßung. (In German). **Langenbecks Arch. Chir. Suppl. Chir. F** rum 1997; 195-9.
  42. Binder J, Kupiec-Weglinski JW: Tolerance and cytokine profiles in sensitized graft recipients. **Transplant. Clin. Immunol.** 1998; 29:97-105.
  43. Kupiec-Weglinski JW: Chronic allograft rejection. **Curr. Opin. Organ Transplant.** 1999; 4:1-2.
  44. Zhai Y, Ghobrial RM, Busuttil RW, Kupiec-Weglinski JW: Th1 and Th2 cytokines in organ transplantation: Paradigm lost? **Critical Reviews in Immunology** 1999; 19:155-72.
  45. Zhai Y, Kupiec-Weglinski JW: What is the role of regulatory T cells in transplantation tolerance? **Curr. Opin. Immunol.** 1999; 11:497-503.
  46. Zhai Y, Kupiec-Weglinski JW: Infectious tolerance: A case for regulatory CD4+ T cells. **Graft** 1999; 2:141-5.
  47. Korom S, De Meester I, Coito A, Graser E, Volk HD, Schwemmler K, Sharpe S, Kupiec-Weglinski JW: Immunomodulatory influence of CD26 dipeptidylpeptidase during acute and accelerated rejection. **Langenbecks Arch. Surg.** 1999; 241-5.
  48. Coito AJ, de Sousa M, Kupiec-Weglinski JW: Fibronectin in immune responses in organ transplant recipients. **Dev. Immunol.** 2000; 7:239-48.
  49. Coito AJ, Kupiec-Weglinski JW: Extracellular matrix proteins in organ transplantation. **Transplantation** 2000; 69: 2465-73.
  50. Zhai Y, Kupiec-Weglinski JW: Anti-CD4 therapy and infectious tolerance. **Curr. Opin. Organ Transplant.** 2000; 5:4-9.
  51. Coito AJ, Kupiec-Weglinski JW: The emerging role of extracellular matrix. **Graft** 2000; 3:32-6.
  52. Farmer DG, Amersi F, Kupiec-Weglinski JW, Busuttil RW: Current concepts in ischemia and reperfusion injury in the liver. **Transplant. Rev.** 2000; 14:106-26.
  53. Katori M, Anselmo D, Busuttil RW, Kupiec-Weglinski JW: A novel strategy against ischemia and reperfusion injury: cytoprotection with heme oxygenase system. **Transplant. Immunol.** 2002; 9:227-33.
  54. Katori M, Busuttil RW, Kupiec-Weglinski JW: Heme oxygenase 1 system in organ transplantation. **Transplantation** 2002; 74:905-12.
  55. Kupiec-Weglinski JW: Transplantation tolerance. **Curr. Opin. Organ Transplant.** 2003; 8:1.
  56. Zhai Y, Kupiec-Weglinski JW: Alloreactive memory T cells in transplantation tolerance. **Curr. Opin. Organ Transplant.** 2003; 8:13-8.
  57. Fondevila C, Busuttil RW, Kupiec-Weglinski JW: Hepatic ischemia/reperfusion injury - A fresh look. **Exp. Mol. Pathol.** 2003; 74:86-93.
  58. Zhai Y, Kupiec-Weglinski JW: Regulatory T cells in kidney transplant recipients: Active players but to what extent? **J. Am. Soc. Nephrol.** 2003; 14:1706-8.

## PROCEEDINGS OF MEETINGS:

1. Kupiec-Weglinski JW, Olszewski WL, Tilney NL: Changes in lymphocyte migration patterns after heart grafting in rats. **Transplant. Proc.** 1981; 13:1108-10.
2. Kupiec-Weglinski JW, Rowinski WA, Tilney NL: Lymphocyte migration patterns in enhanced heart allograft recipients. **Surg. Forum** 1981; 32:374-6.
3. Kupiec-Weglinski JW, Bordes-Aznar J, Lear PA, Strom TB, Tilney NL: Cyclosporin A allows expression of specific T suppressor lymphocytes in vivo. **Surg. Forum** 1982; 33:336-8.
4. Lear PA, Clason AE, Heidecke CD, Kupiec-Weglinski JW, Strom TB, Tilney NL: Allograft unresponsiveness in B recipients of cardiac allografts. **Surg. Forum** 1982; 33:370-2.
5. Lear PA, Heidecke CD, Kupiec-Weglinski JW, Clason AE, Strom TB, Tilney NL: Reestablishment of immunologic responsiveness toward cardiac allografts in B rats. **Transplant. Proc.** 1983; 15:349-51.
6. Bordes-Aznar J, Lear PA, Strom TB, Tilney NL, Kupiec-Weglinski JW: Kinetics of Cyclosporin-A- induced unresponsiveness to cardiac allografts in rats. **Transplant. Proc.** 1983; 15:500-3.
7. Kupiec-Weglinski JW, Lear PA, Bordes-Aznar J, Tilney NL, Strom TB: Acute rejection in Cyclosporin A-treated graft recipients occurs following abrogation of suppressor cells. **Transplant. Proc.** 1983; 15:531-4.
8. Kupiec-Weglinski JW, Lear PA, Bordes-Aznar J, Heidecke CD, Strom TB, Tilney NL: Restoring immune responsiveness toward cardiac allografts in Cyclosporin-A-treated rats. **Transplant. Proc.** 1983; 15:1917-8.
9. Kupiec-Weglinski JW, Lear PA, Tilney NL: Importance of thymocyte migration in Cyclosporine-treated heart graft recipients. **Surg. Forum** 1983; 34:389-92.
10. Heidecke CD, Lear PA, Kupiec-Weglinski JW, Tilney NL: Requirement for T-cell subsets and lymphokine in reestablishment of alloimmunity in B-rats. **Surg. Forum** 1983; 34:404-6.
11. Kupiec-Weglinski JW, Lear PA, Strom TB, Tilney NL: Population of Cyclophosphamide-sensitive T suppressor cells maintain Cyclosporine-induced allograft survival. **Transplant. Proc.** 1983; 15:2357-63.
12. Kirkman RL, Araujo JL, Huber DJ, Kupiec-Weglinski JW, Adams DF, Tilney NL: Detection of cardiac allograft rejection by proton nuclear magnetic resonance. **Surg. Forum** 1984; 35:365-6.
13. Araujo JL, Kupiec-Weglinski JW, Heidecke CD, Williams JM, Tilney NL: Suppressor cells stop the progression of acute rejection of rat cardiac allografts. **Surg. Forum** 1984; 35:365-6.
14. Strom TB, Kupiec-Weglinski JW, Heidecke CD, Tilney NL: The cellular and molecular basis of allograft rejection: Fact and fancy. **Transplant. Proc.** 1985; 17:801-5.
15. Heidecke CD, Kupiec-Weglinski JW, Abbud-Filho M, Araujo JL, Lear PA, Strom TB, Tilney NL: T helper and T cytotoxic/suppressor cells and lymphokines are critical in acute organ graft rejection in B rats. **Transplant. Proc.** 1985; 17:866-8.
16. Araujo JL, Williams JM, Heidecke CD, Christenson L, Towpik E, Kupiec-Weglinski JW, Tilney NL: Cell cycle analysis and lymphocyte subsets in rejecting rat cardiac allografts. **Transplant. Proc.** 1985; 17:872-4.
17. Salomon DR, Uhteg LC, Rocher LL, Kupiec-Weglinski JW, Araujo JL, Tilney NL, Carpenter CB: Cyclosporine-induced transplantation tolerance: Analysis of two populations of suppressor cells. **Transplant. Proc.** 1985; 17:1336-8.
18. Kupiec-Weglinski JW, Araujo JL, Heidecke CD, Abbud-Filho M, Tilney NL: Does Cyclosporine inhibit T helper or spare T suppressor lymphocytes in the maintenance phase of allograft survival? **Transplant. Proc.** 1985; 17:1339-40.

19. Abbud-Filho M, Kupiec-Weglinski JW, Araujo JL, Heidecke CD, Tilney NL, Strom TB: The role of interleukin-3 and suppressor cells in Cyclosporine-induced graft tolerance. **Transplant. Proc.** 1985; 17:1384-6.
20. Schneider TM, Kupiec-Weglinski JW, Towpik E, Diamantstein T, Strom TB, Tilney NL: Effects of lymphocytes and IL-2R mAb on cardiac graft survival. **Surg. Forum** 1985; 36:366-8.
21. Towpik E, Kupiec-Weglinski JW, Schneider TM, Tyler DS, Tilney NL: Indefinite survival of skin allografts in Cyclosporine-treated rats. **Surg. Forum** 1985; 36:608-10.
22. Padberg WM, Kupiec-Weglinski JW, Lord RH, Tilney NL: Blocking factors give W3/25+ T-cells suppressor properties in enhanced heart-grafted rats. **Surg. Forum** 1986; 37:374-4.
23. Kupiec-Weglinski JW, Padberg WM, Uhteg LC, Strom TB, Diamantstein TB, Tilney NL: Interleukin-2 receptor targeted therapy in organ transplantation. **Surg. Forum** 1986; 37:374-7.
24. Lord RHH, Hancock WW, Colby AJ, Padberg W, Diamantstein T, Kupiec-Weglinski JW, Tilney NL: Effects of anti-IL 2 receptor monoclonal antibody and Cyclosporine on IL 2 receptor-positive cells infiltrating cardiac allografts in rats. **Transplant. Proc.** 1987; 19:354-5.
25. Padberg WM, Kupiec-Weglinski JW, Lord RH, Towpik E, Tilney NL: W3/25+ T cells mediate specific unresponsiveness in enhanced allograft recipients. **Transplant. Proc.** 1987; 19:493-4.
26. Towpik E, Kupiec-Weglinski JW, Uhteg LC, Padberg WM, Tilney NL: Immune responsiveness following skin grafting in Cyclosporine-treated rats. **Transplant. Proc.** 1987; 19:497-8.
27. Kupiec-Weglinski JW, Padberg W, Uhteg LC, Towpik E, Lord RH, Ma L, Diamantstein T, Strom TB, Tilney NL: Anti-interleukin-2 receptor (IL-2R) antibody against rejection of organ grafts. **Transplant. Proc.** 1987; 19:591-3.
28. Uhteg LC, Kupiec-Weglinski JW, Tilney NL, Carpenter CB: Suppression of lymph node CTL generation by spleen cells from cyclosporine-treated cardiac-engrafted rats. **Transplant. Proc.** 1987; 19:1189-90.
29. Tellides G, Dallman MJ, Kupiec-Weglinski JW, Diamantstein T, Morris PJ: Functional blocking of the interleukin-2 receptor (IL-2R) may be important in the efficacy of IL-2R antibody therapy. **Transplant. Proc.** 1987; 19:4231-3.
30. Padberg WM, Di Stefano R, Lord RHH, Araneda D, Strom TB, Strom TB, Diamantstein T, Tilney NL, Kupiec-Weglinski JW: Synergy between Cyclosporine and other immunosuppressive regimens in experimental organ transplantation. **Transplant. Proc.** 1987; 19:4234-5.
31. Lord RHH, Padberg W, Hancock WW, Kupiec-Weglinski JW, Tilney NL: Activation markers in cardiac allografts in rats treated by different immunosuppressive modalities. **Surg. Forum** 1987; 38:341-4.
32. Di Stefano R, Kupiec-Weglinski JW, Puskas J, Stunkel K, Grutzmann R, Diamantstein T, Tilney NL: Therapeutic efficacy of anti-interleukin-2 receptor monoclonal antibodies in experimental organ transplantation. **Surg. Forum** 1987; 38:344-6.
33. Kupiec-Weglinski JW, Austyn JM, Morris PJ: Migration patterns of dendritic cells in the mouse. **Surg. Forum** 1987; 38:359-62.
34. Kupiec-Weglinski JW, Di Stefano R, Stunkel KG, Grutzmann R, Theisen P, Araneda D, Tilney NL, Diamantstein T: Anti-interleukin 2 receptor monoclonal antibody therapy in rat recipients of cardiac allografts: The role of antibody isotype. **Transplant. Proc.** 1988; 20 (Suppl. 1):272-5.
35. Lord RHH, Padberg WM, Di Stefano R, Hancock WW, Rickles FR, Tilney NL, Kupiec-Weglinski JW: Immunohistological profile of cells infiltrating acutely rejecting and long surviving rat cardiac allografts. **Transplant. Proc.** 1988; 20:229-30.
36. Kupiec-Weglinski JW, Hahn HJ, Kirkman RL, Volk HD, Mouzaki A, Di Stefano R, Tellides G, Dallman MJ, Morris PJ, Strom TB, Tilney NL, Diamantstein T: Cyclosporine potentiates the immunosuppressive effects of anti-interleukin 2 receptor monoclonal antibody therapy. **Transplant. Proc.** 1988; 20 (Suppl. 2):207-16.

37. Di Stefano R, Kupiec-Weglinski JW, Uhteg LC, Puskas J, Araneda D, Diamantstein T, Tilney NL: Modulation of accelerated rat cardiac allograft rejection by CsA and ART-18. **Transplant. Proc.** 1988; 20 (Suppl. 2): 217-22.
38. Tilney NL, Strom TB, Kupiec-Weglinski JW: Pharmacological and immunological agonists and antagonists of cyclosporine. **Transplant. Proc.** 1988; 20 (Suppl. 3):13-22.
39. Padberg WM, Lord RH, Araneda D, Tilney NL, Kupiec-Weglinski JW: Synergistic immunosuppressive effect of subtherapeutic doses of cyclosporine A on immunological enhancement in rat recipients of cardiac allografts. **Transplant. Proc.** 1988; (Suppl. 3):1053-6.
40. Ueda H, Kupiec-Weglinski JW, Tanaka K, Tilney NL: Does interleukin 2 receptor targeted therapy influence differentially the host responses against heart or kidney allografts? **Surg. Forum** 1988; 39:360-2.
41. Tilney NL, Kupiec-Weglinski JW: Advances in the understanding of rejection mechanisms. **Transplant. Proc.** 1989; 21:10-3.
42. Lord RHH, Padberg WM, Hancock WW, Kupiec-Weglinski JW, Tilney NL: Correlation of macrophage and NK cell numbers with "activation markers" in rat cardiac allografts. **Transplant. Proc.** 1989; 21:449-50.
43. Tanaka K, Turka LA, Ueda H, Diamantstein T, Milford EL, Carpenter CB, Tilney NL, Kupiec-Weglinski JW: Selective sparing of T suppressor cells by anti interleukin-2 receptor monoclonal antibodies (IL-2R mAbs) in vitro correlates with their therapeutic effects in vivo. **Transplant. Proc.** 1989; 21:475-6.
44. Di Stefano R, Uhteg LC, Hancock WW, Araneda D, Kupiec-Weglinski JW, Tilney NL: Host - graft relationship in accelerated rejection of rat cardiac allografts. **Transplant. Proc.** 1989; 21:496-7.
45. Kupiec-Weglinski JW, van der Meide P, Stunkel KG, Tanaka K, Diamantstein T, Tilney NL: Interleukin 2 receptor directed therapy in rat recipients of cardiac allografts: Synergistic and antagonistic interactions with the gamma interferon network. **Transplant. Proc.** 1989; 21:992-3.
46. Stunkel KG, Grutzmann R, Diamantstein T, Kupiec-Weglinski JW, Schlumberger HD: Anti-interleukin 2 receptor monoclonal antibody therapy in rats: Comparison of the effector mechanisms mediated by variant murine isotypes. **Transplant. Proc.** 1989; 21:1003-5.
47. Ueda H, Hancock WW, Kupiec-Weglinski JW, Tilney NL: Differential effects of anti-IL-2R-targeted therapy on heart and kidney grafts. **Surg. Forum** 1989; 40:383-5.
48. Kupiec-Weglinski JW, Mariani G, Tilney NL: Biodistribution of anti-interleukin 2 receptor monoclonal antibodies. **Surg. Forum** 1989; 40:386-8.
49. Hancock WW, Sablinski T, Milford EL, Tilney NL, Atkins R, Kupiec-Weglinski JW: Beneficial effects of monoclonal antibody targeting of CD4<sup>+</sup> cells during the sensitization but not effector phase of accelerated rejection of rat cardiac allografts. **Transplant. Proc.** 1990; 22:2115-6.
50. Sablinski T, Tilney NL, Hancock WW, Sayegh MH, Milford EL, Kupiec-Weglinski JW: Therapy with anti- CD4 mAb prevents sensitization and prolongs cardiac allograft survival in rats. **Surg. Forum** 1990; 41:387-9.
51. Whitley D, Hancock WW, Kupiec-Weglinski JW, Tilney NL: The role of iron in rejection of vascularized organ allografts. **Surg. Forum** 1990; 41:394-7.
52. Badger AM, Albrightson-Winslow CR, Kupiec-Weglinski JW: SK&F 105685: A novel immunosuppressive compound with efficacy in animal models of autoimmunity and transplantation. **Transplant. Proc.** 1991; 23:194-5.
53. Hancock WW, Tanaka K, Salem HH, Tilney NL, Atkins RC, Kupiec-Weglinski JW: TNF as a mediator of cardiac transplant rejection, including effects on the intragraft protein C/protein S/thrombomodulin pathway. **Transplant. Proc.** 1991; 23:235-7.

54. Sablinski T, Sayegh MH, Kut JP, Hancock WW, Milford EL, Tilney NL, Kupiec-Weglinski JW: Therapeutic strategies targeted at CD4<sup>+</sup> cells obviate accelerated rejection of cardiac allografts in sensitized rats. **Transplant. Pr c.** 1991; 23:268-9.
55. Tanaka K, Kupiec-Weglinski JW, Hancock WW, Stunkel KG, Diamantstein T, Tilney NL: Pretreatment with Cyclosporin A (CyA) and anti-interleukin 2 receptor monoclonal antibody (IL-2R mAb) abrogates the anti-idiotypic response in rat recipients of cardiac allografts. **Transplant. Pr c.** 1991; 23:281-2.
56. Kupiec-Weglinski JW, Sablinski T, Hancock WW, Mix CT, Tilney NL: Synergistic interactions between anti-interleukin-2 receptor (IL-2R) mAb and CyA in sensitized rat recipients of cardiac allografts. **Transplant. Pr c.** 1991; 23:285-6.
57. Papp I, Sablinski T, Wieder KJ, O'Connell PJ, Milford EL, Strom TB, Kupiec-Weglinski JW: The differential effects of CD4 mAb therapy on intragraft expression of IL-2 and IL-4 genes. **Surg. Forum** 1991; 42:380-3.
58. Hancock WW, Whitley D, Kupiec-Weglinski JW, Tilney NL: Oral iron chelator desferriethiocin blocks allogeneic mononuclear cell activation and cytokine production in vivo and prolongs rat cardiac allograft survival. **Transplant. Proc.** 1992; 24:214-5.
59. Hancock WW, Schmidbauer G, Badger AM, Kupiec-Weglinski JW: SK&F 105685 suppresses allogeneically induced mononuclear and endothelial cell activation and cytokine production and prolongs rat cardiac allograft survival. **Transplant. Proc.** 1992; 24:231-2.
60. Sablinski T, Hancock WW, Schmidbauer G, Milford EL, Kupiec-Weglinski JW: CD4 mAb therapy diminishes sensitization to xenoantigen and abrogates hyperacute rejection of hamster cardiac grafts in rats. **Transplant. Pr c.** 1992; 24:528-30.
61. Schmidbauer G, Wieder KJ, Corpier CL, Wieder I, Sablinski T, Strom TB, Kupiec-Weglinski JW: Transcription of interleukin-8-like and cytotoxic T-cell-specific serine esterase genes in allograft recipients is prevented by Rapamycin treatment. **Surg. Forum** 1992; 43:416-9.
62. Sablinski T, Hancock WW, Wasowska BA, Schmidbauer G, Baldwin WM III, Kut JP, Milford EL, Kupiec-Weglinski JW: Modulation of acute and hyperacute rejection of xenografts in concordant hamster-to-rat combination. **Transplant. Proc.** 1993; 25:432-4.
63. Heidecke CD, Hancock WW, Jakobs F, Westerholt S, Sewczek T, Deusch K, Zanti N, Kurrle R, Kupiec-Weglinski JW: TCR  $\alpha/\beta$  targeted therapy in the rat: Pretreatment with R73 monoclonal antibody induces profound immunological anergy and long-term allograft survival. **Transplant. Proc.** 1993; 25:540-2.
64. Schmidbauer G, Hancock WW, Wasowska BA, Sablinski T, Kupiec-Weglinski JW: Rapamycin treatment prevents and/or erases sensitization and abrogates accelerated rejection of vascularized organ allografts. **Transplant. Proc.** 1993; 25:712-3.
65. Schmidbauer G, Hancock WW, Badger AM, Kupiec-Weglinski JW: SK&F 105685 treatment induces suppressor cell activity and modulates cell adhesion properties in rat recipients of cardiac allografts. **Transplant. Proc.** 1993; 25:758-60.
66. Kupiec-Weglinski JW, Coito AJ, Binder J, De Sousa M: The expression of extracellular matrix proteins represents an integral part of the host immune response in organ transplantation. **Surg. Forum** 1993; 44: 415-8.
67. Binder J, Sayegh MH, Watschinger B, Hancock WW, Lehmann M, Volk HD, Kupiec-Weglinski JW: Donor-specific transplantation unresponsiveness in sensitized rats following treatment with a nondepleting anti-CD4 monoclonal antibody. **Surg. Forum** 1994; 45:438-42.
68. Binder J, Hancock WW, Wasowska B, Gallon L, Watschinger B, Sayegh MH, Brock J, Lehmann M, Volk HD, Kupiec-Weglinski JW: Donor-specific transplantation unresponsiveness in sensitized rats following treatment with a nondepleting anti-CD4 mAb is associated with selective intragraft sparing of Th2-like cells. **Transplant. Proc.** 1995; 27:114-6.



69. Binder J, Hancock WW, Watschinger B, Wasowska B, Sayegh MH, Kupiec-Weglinski JW: Abrogation of accelerated allograft rejection by intrathymic injection of donor spleen cells is associated with upregulation of donor-reactive IgM, IgG1 and IgG2a, but depression of IgG2b in the circulation and at the graft site. **Transplant. Proc.** 1995; 27:138-41.
70. Wasowska B, Wieder KJ, Hancock WW, Berse B, Binder J, Strom TB, Kupiec-Weglinski JW: Cytokine and alloantibody networks in long-term cardiac allografts in rapamycin-treated sensitized rat recipients. **Transplant. Proc.** 1995; 27:423-6.
71. Schmidbauer G, Hancock WW, Wasowska B, Binder J, Padberg W, Kupiec-Weglinski JW: Rapamycin abrogates accelerated rejection in sensitized rats by selectively suppressing intragraft cell activation, adhesion/binding properties, and modulating serum alloantibody responses. **Transplant. Proc.** 1995; 27:427-9.
72. Coito AJ, Binder J, Brown LF, de Sousa M, Van De Water L, Kupiec-Weglinski JW: TNF- $\alpha$  upregulates the expression of fibronectin in acutely rejecting rat cardiac allografts. **Transplant. Proc.** 1995; 27:463-5.
73. Onodera K, Binder J, Volk HD, Hancock WW, Sayegh MH, Kupiec-Weglinski JW: Down-regulation of IFN- $\gamma$  rather than IL-2 gene expression is associated with prolonged cardiac allograft (Tx) survival following intrathymic injection of donor cells in sensitized rats. **Surg. Forum** 1995; 46:426-9.
74. Korom S, De Meester I, Onodera K, Stadlbauer THW, Barloo M, Lambeir AM, Kupiec-Weglinski JW: Specific inhibition of CD26/DPP IV abrogates acute allograft rejection. **Surg. Forum** 1996; 47:403-5.
75. Onodera K, Lehmann M, Volk HD, Sayegh MH, Kupiec-Weglinski JW: Induction of "infectious" tolerance to MHC-incompatible cardiac allografts in sensitized rat recipients treated with a nondepleting CD4 mAb. **Surg. Forum** 1996; 47:423-7.
76. Wasowska B, Hancock WW, Onodera K, Korom S, Stadlbauer THW, Zheng XX, Strom TB, Kupiec-Weglinski JW: Rapamycin and Cyclosporine A treatment: A novel regimen to prevent chronic allograft rejection in sensitized hosts. **Transplant. Proc.** 1997; 29:333.
77. Schmidbauer G, Homeyer A, Bohle RM, Grimm H, Binder J, Kupiec-Weglinski JW: Donor pretreatment with Methylprednisolone synergistically prolongs survival of cardiac allografts in sensitized rat recipients conditioned with Rapamycin. **Transplant. Proc.** 1997; 29:607-8.
78. Stadlbauer THW, Onodera K, Schaub M, Korom S, Binder J, Sayegh MH, Kupiec-Weglinski JW: Intrathymic immunomodulation of sensitized rat recipients of cardiac allografts: Requirements for allorecognition pathways. **Transplant. Proc.** 1997; 29:1016.
79. Coito A, Korom S, Van De Water L, Kupiec-Weglinski JW: Distinct fibronectin splicing variants: Potential targets for therapeutic immunomodulation in organ allograft recipients. **Transplant. Proc.** 1997; 29:1060-1.
80. Korom S, De Meester I, Onodera K, Stadlbauer THW, Barloo M, Lambeir AM, Kupiec-Weglinski JW: The effects of CD26/DPP IV-targeted therapy on acute allograft rejection. **Transplant. Proc.** 1997; 29:1274-5.
81. Onodera K, Hancock WW, Graser E, Volk HD, Lehmann M, Chandraker A, Sayegh MH, Kupiec-Weglinski JW: Th2-type cytokines in the "infectious" tolerance pathway. **Transplant. Proc.** 1997; 29:1290-1.
82. Graser E, Risch K, Linsley PS, Hancock WW, Muller A, Brock J, Reinke P, Kupiec-Weglinski JW, Volk HD, Lehmann M: Synergism of CTLA4-Ig and anti-CD4 monoclonal antibody treatment in a rat kidney transplant model. **Transplant. Proc.** 1997; 29:1307-9.
83. Onodera K, Lehmann M, Volk HD, Sayegh MH, Kupiec-Weglinski JW: CD4-targeted therapy induces "infectious" tolerance to cardiac allografts in sensitized rat recipients. **Transplant. Proc.** 1997; 29:1907-8.
84. Kupiec-Weglinski JW, Coito AJ, Van De Water L: Extracellular matrix proteins and their interactions with the cellular repertoire of transplant recipients. **Transplant. Proc.** 1997; 29:2595-6.

85. Korom S, Hancock WW, Coito AJ, Kupiec-Weglinski JW: Blockade of VLA-4 integrin - fibronectin adhesive interactions in vivo: A novel approach to prevent chronic rejection. **Surg. Forum** 1997; 48:453-6.
86. Onodera K, Chandraker A, Volk HD, Lehmann M, Korom S, Stadlbauer TH, Kato K, Kasai S, Sayegh MH, Kupiec-Weglinski JW: Role of regulatory T cells in the "infectious" tolerance pathway in transplant recipients. **Transplant. Proc.** 1998; 30:13-5.
87. Onodera K, Chandraker A, Korom S, Stadlbauer TH, Kato K, Kasai S, Sayegh MH, Kupiec-Weglinski JW: Agonistic and antagonistic interactions between CTLA4Ig and donor alloantigens in sensitized rat recipients of cardiac allografts. **Transplant. Proc.** 1998; 30:16-8.
88. Coito AJ, Korom S, Hancock WW, Kupiec-Weglinski JW: Blockade of  $\alpha 4\beta 1$ -integrin - fibronectin adhesive interactions prevents chronic allograft rejection in sensitized recipients. **Transplant. Proc.** 1998; 30:939-40.
89. Binder J, Braeutigam R, Oertl A, Kramer W, Jonas D, Hancock WW, Kupiec-Weglinski JW: Methylprednisolone in bilayer liposomes prolongs cardiac and renal allograft survival, inhibits macrophage activation, and selectively modifies antigen presentation and T-helper cell function in rat recipients. **Transplant. Proc.** 1998; 30:1051.
90. Kato H, Onodera K, Chandraker A, Volk HD, Sayegh MH, Kupiec-Weglinski JW: CD4-targeted therapy and CD28-B7 costimulatory blockage may independently induce tolerance in sensitized allograft recipients. **Transplant. Proc.** 1998; 30:1063-4.
91. Kupiec-Weglinski JW, Onodera K, Volk HD: The "infectious" tolerance pathway in organ allograft recipients. **Transplant Proc.** 1998; 30:1595-7.
92. Coito AJ, Onodera K, Kupiec-Weglinski JW: Distinct roles of fibronectin expression by endothelial cells and macrophages in the infectious tolerance pathway in allograft recipients. **Surg. Forum** 1998; 49:373-5.
93. Maggard M, Johnson C, Wang T, Terasaki P, Kupiec-Weglinski JW, Busuttil RW, Imagawa DK: Inhibition of transplant vasculopathy is associated with attenuation of host allo-antibody responses. **Transplant. Proc.** 1999; 31:728-9.
94. Korom S, De Meester I, Schmidbauer G, Pratschke J, Brendel MD, Durinx C, Schwemmler K, Haemers A, Scharpe S, Kupiec-Weglinski JW: Specific inhibition of CD26/DPP IV enzymatic activity in allograft recipients: effects on humoral immunity. **Transplant. Proc.** 1999; 31:778.
95. Korom S, De Meester I, Coito AJ, Graser E, Pratschke J, König S, Grimm H, Volk HD, Scharpe S, Kupiec-Weglinski JW: CD26/DPP IV-mediated modulation of acute rejection. **Transplant. Proc.** 1999; 31:873.
96. Onodera K, Chandraker A, Kato H, Volk HD, Sayegh MH, Kupiec-Weglinski JW: Distinct tolerance pathways in sensitized rat recipients after blockade of activation signal 1 and signal 2. **Transplant. Proc.** 1999; 31:876-7.
97. Kato H, Ritter T, Ke B, Busuttil R, Kupiec-Weglinski JW: Gene transfer of IL-4 prolongs rat renal allograft survival and inhibits p21<sup>ras</sup> activation pathway. **Surg. Forum** 1999; 50:381-3.
98. Amersi F, Buelow R, Farmer D, Kato H, Ke B, Ghobrial M, Busuttil RW, Kupiec-Weglinski JW: Heme oxygenase-1 overexpression protects genetically fat Zucker rat livers from ischemia/reperfusion injury. **Surg Forum** 1999; 50:385-7.
99. Reemtsen BL, Zhai Y, Stepkowski S, Kahan BD, Busuttil RW, Kupiec-Weglinski JW, Ghobrial RM: Immunogenicity of the  $\alpha 1$ -helical region of rat RT1.A class I MHC antigens. **Surg. Forum** 1999; 50:395-7.
100. Kato H, Ritter T, Ke B, Murakami M, Kusano M, Busuttil RW, Kupiec-Weglinski JW: Adenovirus-mediated gene transfer of IL-4 prolongs rat renal allograft survival and inhibits the p21(ras)-activation pathway. **Transplant. Proc.** 2000; 32:245-6.
101. Ghobrial RM, Mhoyan A, Zhai Y, Shen XD, Zhao D, Gao F, Reemtsen BL, Singer J, Kahan B, Busuttil RW, Kupiec-Weglinski JW: Induction of tolerance by allochimeric class I MHC molecules: Evidence of immunoregulatory T cells and limited usage of T cell receptor V $\beta$  genes. **Surg. Forum** 2000; 51:324-6.

102. Katori M, Buelow R, Ke B, Ma J, Coito AJ, Busuttil RW, Kupiec-Weglinski JW: Cobalt protoporphyrin-induced overexpression of heme oxygenase-1 protects rat hearts from cold ischemia/reperfusion injury via anti-apoptotic pathway. **Surg. Forum** 2000; **51**:335-6.
103. Tanabe Y, Omori K, Hao D, Valiente L, Maruyama M, Smith CV, Weglinski JK, Busuttil RW, Mullen Y, Ghobrial RM: Induction of long-term islet allograft survival in two rat strains by a single allochimeric class I MHC molecule. **Transplant. Proc.** 2001; **33**:157-8.
104. Singer JS, Shen X, Fishbein M, Mhoyan A, Zhao D, Reemtsen B, Gao F, Amersi F, Coito AJ, Busuttil RW, Weglinski JK, Ghobrial RM: Allochimeric class I MHC inhibits chronic rejection in cardiac allografts. **Transplant. Proc.** 2001; **33**:179.
105. Kupiec-Weglinski JW, Shen XD, Gao F, Zhai Y, Coito AJ, Sayegh MH: CD40 ligand – CD40 T cell costimulation pathway is required for host sensitization in the immune cascade leading to accelerated allograft rejection. **Transplant. Proc.** 2001; **33**:304-5.
106. Coito AJ, Kato H, Azimi R, Kupiec-Weglinski JW: Chronic allograft rejection versus tolerance: a critical role for EIIIA(+) fibronectin. **Transplant. Proc.** 2001; **33**:526-7.
107. Ghobrial RM, Amersi F, Stecker K, Kato H, Melinek J, Singer J, Mhoyan A, Busuttil RW, Kupiec-Weglinski JW, Stepkowski SM: Amelioration of hepatic ischemia/reperfusion injury with intercellular adhesion molecule-1 anti-sense oligonucleotides. **Transplant. Proc.** 2001; **33**:538.
108. Ke B, Shen XD, Melinek J, Gao F, Ritter T, Volk HD, Busuttil RW, Kupiec-Weglinski JW: Heme oxygenase-1 gene therapy: A novel immunomodulatory approach in liver allograft recipients? **Transplant. Proc.** 2001; **33**:581-2.
109. Sawitzki B, Lehmann M, Ritter T, Graser E, Kupiec-Weglinski JW, Volk HD: Regulatory tolerance-mediating T cells in transplantation tolerance. **Transplant. Proc.** 2001; **33**:2092-3.
110. Semiletova N, Shen XD, Gao F, Bridges L, Anselmo D, Busuttil RW, Kupiec-Weglinski JW, Ghobrial R: Inhibition of apoptosis by regulatory T cells following allochimeric MHC I therapy. **Surg. Forum** 2001; **52**:294-5.
111. Farmer DG, Amersi F, Shen XD, Gao F, Ma J, Anselmo D, Busuttil RW, Kupiec-Weglinski JW: P-selectin glycoprotein ligand-1 immunoglobulin improves survival and reduces inflammation after ischemia and reperfusion injury in rat intestinal transplantation. **Surg. Forum** 2001; **52**:304-5.
112. Anselmo DM, Amersi FF, Shen XD, Gao F, Lassman C, Zhai Y, Brinkmann V, Kupiec-Weglinski JW, Busuttil RW, Farmer DG: FTY720: A novel therapeutic approach to the reduction of hepatic ischemia/reperfusion injury. **Surg. Forum** 2001; **52**:306-7.
113. Amersi F, Shen XD, Anselmo D, Melinek J, Gao F, Busuttil RW, Buelow R, Kupiec-Weglinski JW: Heme oxygenase-1/carbon monoxide signaling pathway in hepatic ischemia/reperfusion injury. **Surg. Forum** 2001; **52**:308-10.
114. Farmer DG, Amersi F, Shen XD, Gao F, Anselmo D, Ma J, Dry S, McDiarmid SV, Shaw G, Busuttil RW, Kupiec-Weglinski J: Improved survival through the reduction of ischemia-reperfusion injury after rat intestinal transplantation using selective P-selectin blockade with P-selectin glycoprotein ligand-IG. **Transplant. Proc.** 2002; **34**:985.
115. Semiletova N, Shen XD, Gao F, Slomowitz SJ, Jiao Q, Busuttil RW, Kupiec-Weglinski JW: Regulatory T cells induced by allochimeric major histocompatibility class I therapy inhibit allograft apoptosis. **Transplant. Proc.** 2002; **34**:1402.
116. Coito AJ, Shaw GD, Meng L, Moore C, Ma J, Busuttil RW, Kupiec-Weglinski JW: CD62 - PSGL-1 interactions regulate cytokine chemokine and apoptotic networks in cardiac allograft recipients. **Transplant. Proc.** 2002; **34**:1463-4.

117. Ke B, Shen XD, Buelow R, Melinek J, Amersi F, Gao F, Ritter T, Volk HD, Busuttil RW, Kupiec-Weglinski JW: Heme oxygenase-1 gene transfer prevents CD95/FasL-mediated apoptosis and improves liver allograft survival via carbon monoxide signaling pathway. **Transplant. Pr c.** 2002; **34**:1465-6.
118. Anselmo DM, Amersi FF, Shen XD, Gao F, Katori M, Ke B, Lassman C, Coito AJ, Brinkman V, Busuttil RW, Kupiec-Weglinski JW, Farmer DG. FTY720: A novel approach to the treatment of hepatic ischemia-reperfusion injury. **Transplant. Proc.** 2002; **34**:1467-8.
119. Korom S, De Meester I, Maas E, Stein A, Wilker S, Jung F, Weimer R, Brendel MD, Ernst W, Friemann S, Linder R, Grimm H, Padberg W, Scharpe S, Kupiec-Weglinski JW, Schwemmler K: CD26 expression and enzymatic activity in recipients of kidney allografts. **Transplant. Proc.** 2002; **34**:1753-4.
120. Kupiec-Weglinski JW. Interactions between pharmaceutical industry and academia revisited: the University of California at Los Angeles case. **Transplant Proc.** 2003; **35**:1238-9.
121. Fondevila C, Katori M, Lassman C, Carmody I, Busuttil RW, Bach FH, Kupiec-Weglinski JW. Biliverdin protects rat livers from ischemia/reperfusion injury. **Transplant Proc.** 2003; **35**:1798-9.

#### BOOK CHAPTERS:

1. Strom TB, Kupiec-Weglinski JW, Tilney NL: On the mechanism of rejection of vascularized organ allografts: A review and an attempt at synthesis. In: **Morris PJ & Tilney NL (ed): Progress in Transplantation.** Churchill Livingstone, Inc.; 1985; 126-46.
2. Tilney NL, Kupiec-Weglinski JW, Strom TB: T cells and their products in host responsiveness to organ allografts. In: **Meryman HT (ed): Transplantation: Approaches to Graft Rejection.** Alan R. Liss Inc.; 1986; 21-39.
3. Strom TB, Gaulton GN, Kelley VE, Diamantstein T, Kupiec-Weglinski JW, Tilney NL, Kirkman RL: Treatment with anti-interleukin 2 receptor monoclonal antibody. In: **Meryman HT (ed): Transplantation: Approaches to Graft Rejection.** Alan R. Liss, Inc.; 1986; 227-38.
4. Towpik E, Kupiec-Weglinski JW: Use of Cyclosporine in transplantation of non-primary vascularized tissues. In: **Morris PJ & Tilney NL (ed): Transplantation Reviews.** Grune & Stratton, Inc.; 1987; 85-100.
5. Diamantstein T, Osawa H, Kirkman RL, Shapiro ME, Strom TB, Tilney NL, Kupiec-Weglinski JW: Interleukin 2 receptor - A target for immunosuppressive therapy. In: **Morris PJ & Tilney NL (ed): Transplantation Reviews.** Grune & Stratton, Inc.; 1987; 177-96.
6. Strom TB, Gaulton GN, Kelley VE, Diamantstein T, Kupiec-Weglinski JW, Tilney NL, Kirkman RL: Treatment of cardiac transplant recipients with anti-interleukin 2 receptor monoclonal antibody. In: **Kawai C & Abelmann WH (ed): Pathogenesis of Myocarditis and Cardiomyopathy.** University of Tokyo Press; 1987; 173-9.
7. Kupiec-Weglinski JW, Strom TB, Tilney NL: Sparing of suppressor cells by Cyclosporine in allograft recipients. In: **Goldstein G, Bach JF & Wigzell H (ed): Immune Regulation by Characterized Polypeptides.** Alan R. Liss, Inc.; 1987; 153-63.
8. Strom TB, Kelley VE, Murphy JR, Osawa H, Tilney NL, Shapiro ME, Kupiec-Weglinski JW, Diamantstein T, Gaulton GN, Kirkman RL: Interleukin-2 receptor directed immunosuppressive therapy. In: **Webb DR, Pierce CW & Cohen S (ed): Molecular Basis of Lymphokine Action.** Humana Press; 1987; 371-89.
9. Strom TB, Kelley VE, Murphy JR, Osawa H, Tilney NL, Shapiro ME, Kupiec-Weglinski JW, Diamantstein T, Gaulton GN, Kirkman RL: Interleukin 2 receptor directed immunosuppressive therapy. In: **Smith KE (ed): Interleukin 2.** Academic Press, Inc.; 1988; 223-36.
10. Diamantstein T, Mouzaki A, Osawa H, Volk HD, Hahn HD, Kirkman RL, Strom TB, Tilney NL, Kupiec-Weglinski JW: Inhibition of allograft rejection and organ specific autoimmune disease by anti-interleukin 2 receptor (IL-2R) targeted immunotherapy. The action of anti-interleukin IL-2R monoclonal antibodies and synergistic effect of

Cyclosporin A. In: **20th IABS Congress on Cytokines: Laboratory and Clinical Evaluation. Developmental Biology Standard.** S. Karger; 1988; 69:177-84.

11. Tilney NL, Kupiec-Weglinski JW: The immunobiology of acute allograft rejection. In: **Brent L & Sells RA (ed): Organ Transplantation: Current Clinical and Immunological Concepts.** Bailliere's Tindall, Inc. 1989; 19-38.

12. Mouzaki A, Kupiec-Weglinski JW, Volk HD, Diamantstein T: In vivo action of anti-interleukin 2 receptor (IL2R) monoclonal antibodies (mAb). In: **Kaplan JG, Green DR & Bleackley RC (ed): Cellular Basis of Immune Modulation.** Alan R. Liss, Inc.; 1989; 547-50.

13. Diamantstein T, Tilney NL, Strom TB, van der Meide P, Hahn HJ, Volk HD, Weetman AP, Kupiec-Weglinski JW: Interleukin-2 receptor targeted immunosuppressive therapy with anti-interleukin-2 receptor mAbs directed against L-chain of the interleukin-2 receptor: Studies of selectivity and mode of action. In: **Hadden JW et al. (ed): Advances in Immunopharmacology IV.** Pergamon Press; 1989; 95-104.

14. Diamantstein T, Volk HD, Hahn HJ, Tilney NL, Kupiec-Weglinski JW: Interleukin 2 receptor (IL-2R) targeted immunotherapy - update and an attempt at synthesis. In: **Melchers F et al. (ed): Progress in Immunology VII.** Springer-Verlag; 1989; 619-26.

15. Volk HD, Diamantstein T, Hahn HJ, Kupiec-Weglinski JW, von Baehr R: A new strategy to combat graft rejection in organ transplantation and autoimmune diseases by a short-term selective immunosuppression. (In German). In: **von Baehr R et al. (ed): Monoklonale Antikörper Anwendung in der Medizin.** Springer-Verlag; 1989; 205-8.

16. Tullius SG, Sablinski T, Heemann UW, Kupiec-Weglinski JW, Tilney NL: Immunobiology of heart rejection in experimental models. In: **Rose M & Yacoub M (ed): Immunology of Heart and Lung Transplantation.** Edward Arnold, Inc.; 1993; 42-57.

17. Kupiec-Weglinski JW, Schmidbauer G, Badger AM: SK&F 105685: a novel azaspirane with immunosuppressive activities in animal models of autoimmune diseases and organ transplantation. In: **Thomson A & Starzl T (ed): Immunosuppressive Drugs: Development in Anti-Rejection Therapy.** Edward Arnold, Inc.; 1994; 213-20.

18. Kupiec-Weglinski JW, Badger AM: SK&F 105685: A novel azaspirane with therapeutic effects in transplantation models. In: **Przepiorka D & Sollinger H (ed): Recent Developments in Transplantation Medicine. Volume I. New Immunosuppressive Drugs.** Physicians & Scientists Publishing Co., Inc.; 1994; 179-90.

19. Badger AM, Kupiec-Weglinski JW: Azaspiranes with therapeutic activity in animal models of autoimmune disease and organ transplantation. In: Kupiec-Weglinski JW (ed): Medical Intelligence Unit. New Immunosuppressive Modalities and Anti-Rejection Approaches in Organ Transplantation. RG Landes Co.; 1994; 93-105.

20. Kupiec-Weglinski JW, Tilney NL: Immunopharmacology in the transplantation of vascularized organ allografts. In: **Zierhut M, Pleyer U & Thiel H-J (ed): Immunology of Corneal Transplantation.** Aeolus Press Science Publishers; 1994; 197-212.

21. Kupiec-Weglinski JW, Strom TB: Novel immunosuppressive approaches in organ transplantation. In: **Zierhut M, Pleyer U & Thiel H-J (ed): Immunology of Corneal Transplantation.** Aeolus Press Science Publishers; 1994; 213-31.

22. Kupiec-Weglinski JW, de Sousa M: Adhesion molecule interactions with the extracellular matrix. In: **Salomon D & Sollinger H (ed): Recent Developments in Transplantation Medicine. Volume II. Intercellular Adhesion Molecules and Monoclonal Antibodies.** Physicians & Scientists Publishing Co., Inc.; 1995; 123-38.

23. Kupiec-Weglinski JW, Gorski A, Van De Water L: Extracellular Matrix Proteins in Organ Allograft Rejection. In: **Tilney NL, Strom TB & Paul LC (ed): Transplantation Biology: Cellular and Molecular Aspects.** Lippincott-Raven Publishers; 1996; 151-61.

24. Kupiec-Weglinski JW, Hancock WW: Hyperacute and accelerated allograft rejection. In: **Tilney NL, Strom TB & Paul LC (ed): Transplantation Biology: Cellular and Molecular Aspects.** Lippincott-Raven Publishers; 1996; 541-56.

25. Kupiec-Weglinski JW, Paul LC: Cellular and extracellular matrix adhesion molecules in organ transplantation. In: Paul LC & Issekutz TB (ed): **Adhesion Molecules in Health and Disease**. Marcel Dekker, Inc. 1997; 679-708.

26. Kupiec-Weglinski JW: Allograft rejection – Fact and fancy. In: Lukiewicz SJ & Zwiiler JL (ed): **Nitric Oxide in Allograft Rejection and Anti-Tumor Responses**. Kluwer Academic Publishers; 1998; 137-44.

#### **BOOKS AND MONOGRAPHS:**

1. Kupiec-Weglinski JW (ed): New immunosuppressive modalities and anti-rejection approaches in organ transplantation. **R.G. Landes Company Biomedical Publishers, Austin TX; 1994; 1-177.**